



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 213/80, 213/79, 257/04, 307/79, C07C 215/30, 217/16, 255/59, A61K 31/19, 31/24, 31/34, 31/44, 31/41</p>	A1	<p>(11) International Publication Number: WO 99/65877</p> <p>(43) International Publication Date: 23 December 1999 (23.12.99)</p>
<p>(21) International Application Number: PCT/EP99/03958</p> <p>(22) International Filing Date: 9 June 1999 (09.06.99)</p> <p>(30) Priority Data: 9812709.5 13 June 1998 (13.06.98) GB</p> <p>(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): DONALDSON, Kelly, Horne [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). SHEARER, Barry, George [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). UEHLING, David, Edward [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US).</p> <p>(74) Agent: LEAROYD, Stephanie, Anne; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: THERAPEUTIC BIARYL DERIVATIVES</p> <div style="text-align: center;"> <p>(I)</p> </div> <p>(57) Abstract</p> <p>The present invention relates to therapeutic biaryl derivatives of formula (I), and pharmaceutically acceptable derivatives thereof; wherein R¹ is a phenyl, naphthyl, pyridyl, thiazolyl, phenoxyethyl, or pyrimidyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C₁-alkoxy, C₁-alkyl, nitro, cyano, hydroxymethyl, trifluoromethyl, -NR⁶R⁶, and -NHSO₂R⁶, where each R⁶ is independently hydrogen or C₁-alkyl; R² is hydrogen or C₁-alkyl; X is oxygen, sulfur, -NH-, or -NC₁-alkyl; R³ is cyano, tetrazol-5-yl, or -CO₂R⁷ where R⁷ is hydrogen or C₁-alkyl; R⁴ and R⁵ are independently hydrogen, C₁-alkyl, -CO₂H, -CO₂C₁-alkyl, cyano, tetrazol-5-yl, halogen, trifluoromethyl, or C₁-alkoxy, or, when R⁴ and R⁵ are bonded to adjacent carbon atoms, R⁴ and R⁵ may, together with the carbon atoms to which they are bonded, form a fused 5 or 6 membered ring optionally containing one or two nitrogen, oxygen, or sulfur atoms; and Y is N or CH, to processes for their preparation and their use in the treatment of diseases susceptible to amelioration by treatment with a beta-3 adrenoceptor agonist.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Therapeutic Biaryl Derivatives

Field of the Invention

This invention relates to a new class of chemical compounds and to their use in medicine. In particular, the invention relates to biaryl derivatives, methods for their preparation, pharmaceutical compositions containing them, and their use as agonists at atypical beta-adrenoceptors (also known as beta-3-adrenoceptors).

Background of the Invention

Atypical beta-adrenoceptors belong to the family of adrenoceptors which mediate the physiological actions of the hormones adrenaline and noradrenaline. Such receptors have been described for example by J R S Arch *et. al.*, *Nature*, 309, 163-165 (1984); C Wilson *et. al.*, *Eur. J. Pharmacol.*, 100, 309-319 (1984); L J Emorine *et. al.*, *Science*, 245, 1118-1121 (1989); and A. Bianchetti *et. al. Br. J. Pharmacol.*, 100, 831-839 (1990).


Phenethanolamine derivatives having activity at atypical beta-adrenoceptors are disclosed in, for example, European Patent Applications EP-A-0455006 and EP-A-0543662.

Sub-types of the adrenoceptors, α_1 -, α_2 -, β_1 -, β_2 - and β_3 -(atypical) can be identified on the basis of their pharmacological properties and physiological effects. Chemical agents which stimulate or block these receptors (but not β_3) are widely used in clinical medicine. More recently, emphasis has been placed upon specific receptor selectivity in order to reduce side effects caused, in part, by interactions with other receptors.

Atypical beta-adrenoceptors are known to occur in adipose tissue and the gastrointestinal tract. Atypical beta-adrenoceptor agonists have been found to be particularly useful as thermogenic anti-obesity agents and as anti-diabetic agents. Compounds having atypical beta-adrenoceptor agonist activity have also been described as being useful in the treatment of hyperglycaemia, as animal growth promoters, as blood platelet aggregation inhibitors, as positive inotropic agents and as antiatherosclerotic agents, and as being useful in the treatment of glaucoma.

Summary of the Invention

Briefly, in one aspect, the invention therefore provides compounds of Formula (I) and pharmaceutically derivatives thereof:



5

wherein

- R^1 is a phenyl, naphthyl, pyridyl, thiazolyl, phenoxyethyl, or pyrimidyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C_{1-6} alkoxy, C_{1-6} alkyl, nitro, cyano, hydroxymethyl, trifluoromethyl, $-NR^6R^6$, and $-NHSO_2R^6$, where each R^6 is independently hydrogen or C_{1-4} alkyl;
- R^2 is hydrogen or C_{1-6} alkyl;
- X is oxygen, sulfur, $-NH$, or $-NC_{1-4}$ alkyl;
- R^3 is cyano, tetrazol-5-yl, or $-CO_2R^7$ where R^7 is hydrogen or C_{1-6} alkyl;
- R^4 and R^5 are independently hydrogen, C_{1-6} alkyl, $-CO_2H$, $-CO_2C_{1-6}$ alkyl, cyano, tetrazol-5-yl, halogen, trifluoromethyl, or C_{1-6} alkoxy, or, when R^4 and R^5 are bonded to adjacent carbon atoms, R^4 and R^5 may, together with the carbon atoms to which they are bonded, form a fused 5 or 6 membered ring optionally containing one or two nitrogen, oxygen, or sulfur atoms; and
- Y is N or CH.

20

The compounds of the present invention are of use in medical therapy.

Preferably the compounds of this invention are agonists for human beta-3 adrenoceptor (" β_3 "). More preferably, the compounds of this invention are selective agonists for β_3 .

25

In another aspect, the present invention provides a pharmaceutical formulation comprising a compound of the invention, or a pharmaceutically acceptable derivative thereof, and one or more pharmaceutically acceptable carriers.

30

In another aspect, the present invention provides a method for the prevention or treatment of clinical conditions or diseases susceptible to amelioration by

administration of an atypical beta-adrenoceptor agonist, comprising administration of an effective amount of a compound or composition of this invention, or a pharmaceutically acceptable derivative thereof.

5 In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment of conditions or diseases susceptible to amelioration by administration of an atypical beta-adrenoceptor agonist.

10 Detailed Description of the Invention

As used herein, the terms 'alkyl' and "alkoxy" mean a straight or branched alkyl group or alkoxy group respectively, containing the indicated number of carbon atoms. For example, C₁₋₆alkyl means a straight or branched alkyl containing at least 1 and at most 6 carbon atoms.

15 Preferably, R¹ is phenoxymethyl or phenyl optionally substituted by one, two or three substituents selected from halogen, hydroxy, C₁₋₆alkoxy, C₁₋₆alkyl, nitro, cyano, hydroxymethyl and trifluoromethyl. More preferably, R¹ is phenoxymethyl or phenyl substituted by a chlorine, fluorine or bromine atom or a methyl or trifluoromethyl group, which atom or group is preferably located in the meta position. Most preferably R¹ represents phenyl substituted by a chlorine atom located in the meta position.

Preferably, R² is hydrogen or methyl. Most preferably R² is hydrogen,

Preferably, X is -NH or -NCH₃. Most preferably, X is -NH.

25 Preferably, R³ is -CO₂H. Preferably, R³ is bonded to the carbon atom meta or para to the bonded phenyl ring, more preferably the meta position.

Preferably, R⁴ and R⁵ are independently hydrogen, methyl, trifluoromethyl, -CO₂H or, where R⁴ and R⁵ are bonded to adjacent carbon atoms, R⁴ and R⁵, together with the carbon atoms to which they are bonded, form a fused dihydro-furan ring. More preferably, R⁴ and R⁵ are independently hydrogen, methyl, or trifluoromethyl. Preferably, at least one of R⁴ and R⁵ is hydrogen. Most preferably, both R⁴ and R⁵ are hydrogen.

Preferably Y is CH.

Particularly preferred compounds of the invention include those in which
35 each variable in Formula (I) is selected from the preferred groups for each

variable. Even more preferable compounds of the invention include those where each variable in Formula (I) is selected from the more preferred or most preferred groups for each variable.

It will be appreciated that the above compounds of Formula (I) may contain optically active centers. The individual, isolated isomers and mixtures thereof, including racemates, are all within the scope of the present invention. Typically, where R^2 is C_{1-6} alkyl, mixtures of diastereomers of compounds of Formula (I) may be obtained, which are enriched with greater than or equal to 80% by weight of one diastereomer. Particularly preferred compounds of Formula (I) are those wherein the asymmetric carbon atoms in the $-CH(OH)-$ group and the $-CH(R^2)-$ group are both in the (R)-configuration.

Suitable compounds of Formula (I) of the invention include:

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid dimethyl ester;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2-methyl-5-carboxylic acid methyl ester;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3,4-dicarboxylic acid dimethyl ester;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-chloro-4-carboxylic acid methyl ester;

(R)-3'-[[2-[[2-(3,5-dichlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester;

(R)-3'-[[2-[[2-(3,5-dichlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid 2-methyl ester;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2-methyl-5-carboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-chloro-4-carboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3,4-dicarboxylic acid;

5 (R)-3'-[[2-[(2-hydroxy-3-phenoxypropyl)amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid;

(R)-3'-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethoxy]-[1,1'-biphenyl]-3-carboxylic acid;

10 3'-[[2R-[[2-(3-chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]-[1,1'-biphenyl]-4-carboxylic acid;

3'-[[2R-[[2-(3-chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]-[1,1'-biphenyl]-2-carboxylic acid;

3'-[[2R-[[2-(3-chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid;

15 5-[3-[[2R-[[2-(3-chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]phenyl]-3-pyridinecarboxylic acid;

2-[3-[[2R-[[2-(3-chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]phenyl]-3-pyridinecarboxylic acid;

20 (R)-5-[3-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-2,3-dihydro-7-benzofurancarboxylic acid;

(R)-5-[3-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-3-pyridinecarboxylic acid;

(R)-2-[3-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-4-pyridinecarboxylic acid;

25 (R)-6-[3-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-2-pyridinecarboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-(5-tetrazole);

30 (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carbonitrile;

and pharmaceutically acceptable derivatives thereof.

As used herein, "a pharmaceutically acceptable derivative" means a pharmaceutically acceptable salt, ester, or salt of such ester, which, upon administration to the recipient, is capable of providing (directly or indirectly) a
35 compound of Formula (I) or an active metabolite or residue thereof. It will be

appreciated by those skilled in the art that the compounds of Formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds of Formula (I). Of particular interest as such derivatives are compounds modified at the carboxyl function, hydroxyl functions or at amino groups. It will be appreciated by those skilled in the art that the pharmaceutically acceptable derivatives of the compounds of Formula (I) may be derivatised at more than one position.

Preferred pharmaceutically acceptable derivatives of the compounds of Formula (I) are pharmaceutically acceptable salts thereof. Pharmaceutically acceptable salts of the compounds of Formula (I) include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene- p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids. Other acids such as oxalic, while not in themselves pharmaceutically acceptable may be useful in the preparation of salts useful as intermediates in obtaining compounds of the invention and their pharmaceutically acceptable acid addition salts.

Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium), ammonium and NR_4^+ (where R is C_{1-4} alkyl) salts.

The compounds of Formula (I) act as agonists at atypical beta -adrenoceptors and as such are useful in the treatment of clinical conditions susceptible to amelioration by administration of an atypical beta-adrenoceptor agonist. Such conditions include hyperglycaemia, obesity, hyperlipemia, irritable bowel syndrome and its associated pain, motility dysfunction, excessive gastrointestinal secretion, non-specific diarrhea, neurogenic inflammation, regulation of intraocular pressure, triglyceridemia, diabetes, e.g. non-insulin-dependent diabetes mellitus (NIDDM or Type 2), such as obese NIDDM and non-obese NIDDM, diabetic complications such as retinopathy, nephropathy, neuropathy, cataracts, coronary heart diseases and arteriosclerosis, osteoporosis; and gastrointestinal disorders, particularly inflammatory gastrointestinal disorders. They are also of use in increasing the high-density-lipoprotein (HDL) cholesterol concentration and decreasing the triglyceride concentration in blood serum, especially human blood serum, and are therefore of potential use in the treatment and/or prophylaxis of atherosclerosis. They

also may be useful for the treatment of hyperinsulinaemia, depression, muscle wasting, and urinary incontinence. They may also be useful in the preparation of wound-healing medicines. References in this specification to treatment include prophylactic treatment as well as the alleviation of symptoms.

5 In a further aspect, the invention provides the use of a compound of general Formula (I) or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment of a condition susceptible of amelioration by an atypical beta-adrenoceptor agonist.

10 While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical formulation. The invention thus further provides a pharmaceutical formulation comprising a compound of Formula (I) or a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers thereof and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) or excipient(s) must be
15 "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The compounds for use according to the present invention may be formulated for oral, buccal, parenteral, rectal or transdermal administration or in a form
20 suitable for administration by inhalation or insufflation (either through the mouth or the nose).

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g.
25 pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well
30 known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol

syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compounds according to the present invention may be formulated for parenteral administration by injection e.g. by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.


The compounds according to the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously, transcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds according to the present invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Suitable therapeutic ingredients which may be formulated with compounds of the invention, together with one or more pharmaceutical carriers or excipients, include ingredients which may be used in the same clinical conditions as those listed herein for atypical beta-adrenoceptor agonists. Such ingredients may include, for example, PPAR-gamma agonists.

A proposed dose of the compounds according to the present invention for administration to a human (of approximately 70kg body weight) is 0.1mg to 1g, preferably to 1mg to 100mg of the active ingredient per unit dose, expressed as the weight of free base. The unit dose may be administered, for example, 1 to 4 times per day. The dose will depend on the route of administration. It will be appreciated that it may be necessary to make routine variations to the dosage depending on the age and weight of the patient as well as the severity of the condition to be treated. The precise dose and route of administration will ultimately be at the discretion of the attendant physician.

The compounds of the invention may be prepared by any of the processes known in the art for the preparation of similar compounds. For example, according to a first process (A), compounds of Formula (I) may be prepared from of a compound of Formula (II):




where P¹ and P² are suitable protecting groups for oxygen and nitrogen groups respectively, by deprotection of P¹ and P² under suitable conditions such as treatment with an acid, e.g. aqueous hydrochloric acid in a suitable solvent such as dioxane.


As a further process (B), compounds of Formula (I) may be prepared from other compounds of Formula (I). For instance, a compound of Formula (I) where R³ is CO₂H may be prepared from a corresponding ester by hydrolysis, e.g. base hydrolysis with a reagent such as lithium hydroxide in a solvent such as tetrahydrofuran.

Compounds of Formula (II) where X = NH may be prepared by reaction of a compound of Formula (III) with a compound of Formula (IV):

10



(III)



(IV)

where P¹ and P² are suitable protecting groups for oxygen and nitrogen groups respectively.


5 Compounds of Formula (II) where R³ is tetrazol-5-yl may be prepared from compounds of Formula (II) where R³ is cyano, by treatment with, for example, trimethylsilyl azide in a solvent such as toluene.

As a yet further process (C), the preparation of compounds of Formula (II), as defined above, followed by step (A) may be combined without purification of
10 intermediate products.

Compounds of Formula (III) are described in WO95/33724 or may be prepared by standard methods described herein.


Compounds of Formula (IV) may be prepared from compounds of Formula (V). Methods of conversion of compounds of Formula (V) to compounds of
15 Formula (IV) are well known and include, but are not limited to, treatment of a compound of Formula (V) with tin(II) chloride in a suitable solvent such as ethyl acetate or stirring under a hydrogen atmosphere in a suitable solvent such as tetrahydrofuran in the presence of a suitable catalyst such as palladium(0) on carbon.

20




(V)

Compounds of Formula (V) may be prepared by reaction of a compound of Formula (VI) with a compound of Formula (VII) according to the method of Thompson, (*J. Org. Chem.* 1984, 49, 5237) where Z is halogen or triflate.




(VI)




(VII)

According to another process (D), compounds of Formula (I) may be prepared by reaction of a compound of Formula (VIII) with a compound of Formula (IX) in a suitable solvent such as methyl sulfoxide.




(VIII)



(IX)


Compounds of Formula (IX) where X=NH₂ may be prepared by reaction of compounds of Formula (X) with compounds of Formula (IV), in the presence of a suitable reducing agent followed by removal of P² using standard methods.



(X)


A compound of Formula (IX) may also be prepared from a compound of Formula (XI) in the presence of a suitable reducing agent such as borane in tetrahydrofuran followed by removal of P² using standard conditions.

12




(XI)

5 A compound of Formula (XI) where X=NH₂ in turn may be prepared by reaction compound of Formula (IV) with a compound of Formula (XII), in the presence of a suitable agent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.




(XII)

10 A compound of Formula (IX) where X is O may be prepared by the reaction of a compound of Formula (XIII) with a suitable base such as potassium carbonate followed by treatment with a compound of Formula (XIV), where R³ is not CO₂H, followed by removal of P². Referring to Formula (XIII), LG is a leaving
15 group, preferably halogen.




(XIII)



(XIV)


A compound of Formula (XIV) may be prepared by treatment of a compound of Formula (XV), where R³ is not CO₂H, with a suitable reagent such

as boron tribromide. A compound of Formula (XV) may in turn be prepared by treatment of 3-methoxyphenylboronic acid with a compound of Formula (VII) in the presence of a suitable catalyst according to the method described above.




(XV)

Compounds of Formula (XV) may be prepared by reaction of a compound of Formula (XVI) with a compound of Formula (VII) according to the method of Thompson, (*J. Org. Chem.* 1984, 49, 5237) where Z is halogen or triflate.



(XVI)



(VII)

Suitable reducing agents of use in the reactions include hydrogen in the presence of a catalyst, such as a noble metal catalyst, for example palladium, platinum or platinum oxide, Raney-nickel or hydride reducing agents such as borohydrides, for example sodium borohydride, sodium triacetoxyborohydride or sodium cyanoborohydride. Suitable reaction conditions will be readily apparent to those skilled in the art and are further illustrated by the accompanying examples.

The protecting groups used in the preparation of compounds of Formula (I) may be used in conventional manner. See, for example, "Protective Groups in Organic Chemistry", Ed. J. F. W. McOmie (Plenum Press 1973) or "Protective Groups in Organic Synthesis", by Theodora W Greene and P M G Wuts (John Wiley and Sons 1991).

Conventional amino protecting groups may include for example aralkyl groups, such as benzyl, diphenylmethyl or triphenylmethyl groups; and acyl groups such as N-benzyloxycarbonyl or t-butoxycarbonyl.

Conventional oxygen protecting groups may include for example alkyl silyl groups, such as trimethylsilyl, or tert-butyldimethylsilyl; alkylethers such as tetrahydropyranyl, or tert-butyl; or esters such as acetate.

Removal of any protecting groups present may be achieved by conventional procedures.

Atypical beta-adrenoceptor agonists are compounds which demonstrate a pharmacological response mediated at atypical beta-adrenoceptors. This activity has been measured as the ability to stimulate lipolysis by rat adipocytes at sub-micromolar concentrations, in a response that is resistant to blockade by standard beta-adrenoceptor blocking drugs such as propranolol.

Another useful means of identifying an atypical beta-adrenoceptor agonist involves the measurement of agonist activity at atypical beta-adrenoceptors in the rat isolated lower oesophagus. Typically in this assay, a compound of general Formula (I) for use according to the present invention has an equipotent molar ratio (EPMR) relevant to isoprenaline of less than 30. The rat oesophagus assay is based upon that described by Ford *et. al.*, *Br. J. Pharmacol.*, 105(suppl.), 235P, 1992. The relative potency of each test compound (EPMR) is compared to isoprenaline as follows:

$$\text{EPMR} = \frac{\text{EC}_{50} \text{ agonist}}{\text{EC}_{50} \text{ isoprenaline}}$$

wherein EC_{50} is the molar concentration of agonist which produces 50% of the maximum possible response for that agonist.

A particularly useful method for determining agonist activity at human atypical beta-adrenoceptors involves the use of Chinese hamster ovarian (CHO) cells transfected with the human beta-3-adrenoceptor according to Method 1. The cell lines may also be transfected with human beta-1- and beta-2- adrenoceptor in a similar manner to provide a method of determining the selectivity of the compounds of the invention at the three receptors.

Method 1 - Cell culture

General cell culture guidelines are observed (Fershney, R.A. (1987) Culture of animal cells: A manual of basic technique. Wiley-Liss, Inc., N.Y.). A standard cell culture incubator is used (37°C, 5% CO₂ in air, 95% relative humidity). H β_3 CHO cells are grown in DMEM/F12 (with pyroxidine·HCl, 15 mM HEPES, L-glutamine), supplanted with 10% heat-inactivated FBS, 500 μ g/ml G418, 2 mM L-glutamine, 100 units penicillin G and 100 μ g streptomycin sulfate. One confluent flask of cells is trypsinised and resuspended in the above medium at a concentration of 30-40,000 cells/100 μ l and plated into 96-well flat bottom plates. The cells are then used for assay within 18-24 hours.

The medium is aspirated from each well, and replaced with 180 μ l DMEM/F12 with 500 mM IBMX. Antagonists, if required, are added at this stage. The plate is then placed back in the incubator for 30 min. Drugs are then added to the wells (20 μ l, 100x required final concentration) for 60 min. Responses were determined by measuring cAMP levels of a 20 μ l sample of extracellular media using a scintillation proximity based radio-immunoassay (NEN Flashplates).

CHO-6CRE-luciferase cell lines which stably express h β_3 receptors are seeded at 30,000 cells/well for 24 hr in DMEM/F12 containing 10% FBS. Media is removed from the cells and replaced with DMEM/F12 buffer (180 μ l) containing 300 mM IBMX and 1 mM ascorbic acid for 30 min prior to addition of compound. Vehicle or agonist (20 μ l) is added and incubated at 37°C for 60 minutes. At the end of the incubation period, samples of extracellular media are removed for direct assay in cAMP Flashplates (NEN).

As used herein, a compound is considered to be an agonist for h β_3 if the compound stimulates the accumulation of extracellular cAMP with CHO-6CRE-luciferase cells expressing h β_3 . Preferably, the compounds of this invention have an EC₅₀ of at most 100 nM at h β_3 . More preferably, the compounds of this invention have an EC₅₀ of at most 1 nM at h β_3 . The relative potency of a h β_3 agonist may be compared to its potency for stimulating the accumulation of extracellular cAMP with CHO-6CRE-luciferase cells expressing h β_2 and h β_1 . Preferably, the compounds of this invention are at least 100 times more potent at h β_3 than at h β_2 or h β_1 . More preferably, the compounds of this invention are at least 300 times more potent at h β_3 than at h β_2 or h β_1 . The compounds of Examples 9, 10, 11, 12, 13, 14, 16, 17, 20, 21, 22, 23, and 24 have an EC₅₀ of

at most 100 nM at $h\beta_3$ and are at least 100 times more potent at $h\beta_3$ than at $h\beta_2$ or $h\beta_1$. Examples 10, 13, 16, 20, and 24 have an EC_{50} of at most 1 nM and are greater than 300-fold selective at $h\beta_2$ and $h\beta_1$.

5

Examples

The invention is further illustrated by the following intermediates and examples. All temperatures are in degrees centigrade. HPLC characterization was carried out where specified using a Dynamax-60A C18 83-201-C, 25cm x 4.6mm column, eluting with 5-40% CH_3CN in H_2O with 0.1% TFA buffer, with a program time of 30.0 min and flow rate of 1.5mL/min). Retention times are expressed as t_r in minutes. Optical rotation values are expressed as $[\alpha]_D$ values. Mass spectra (ms) were obtained using electrospray (positive or negative ion) analysis. 1H nmr was carried out in deuterated chloroform, unless otherwise indicated.

15

Intermediate 1

Methyl 4-bromo-2-chlorobenzoate

To anhydrous methanol (45 mL) was added acetyl chloride (1.9 mL) over 2 min. The mixture, which became slightly exothermic and evolved gas, was stirred for 15 min. 4-Bromo-2-chlorobenzoic acid (3.0 g) was added in one portion and the mixture was heated at gentle reflux for 16 h. The mixture was allowed to cool to room temperature and the solvent was removed with a rotary evaporator. The residue was partitioned between saturated aqueous sodium bicarbonate and diethyl ether. The organic layer was separated, dried over sodium sulfate, filtered and concentrated to afford the title compound as a white solid (2.89 g).

25

n.m.r. δ values include 3.90 (s, 3H), 7.44 (dd, 1H), 7.62 (d, 1H), 7.70 (d, 1H).

m.p. 28-30 °C

30

Similarly prepared were:

Intermediate 2

Methyl 3-bromo-4-methylbenzoate as a pale yellow oil (2.61 g);

35

n.m.r. δ values include 2.40 (s, 3H), 3.90 (s, 3H), 7.25 (d, 1H), 7.80 (d, 1H), 8.15 (s, 1H),

from 3-bromo-4-methylbenzoic acid (2.63 g) and acetyl chloride (1.8 mL).

Intermediate 3

Dimethyl 4-bromophthalate as a pale yellow oil (3.1 g);

- 5 n.m.r. (DMSO- d_6) δ values include 3.79 (s, 3H), 3.80 (s, 3H), 7.68 (d, 1H), 7.86 (dd, 1H), 7.89 (d, 1H),
from 4-bromophthalic acid (3.0 g) and acetyl chloride (1.8 mL) in anhydrous methanol (50 mL).

10 Intermediate 4

Dimethyl 4-bromoisophthalate as a white solid (3.09 g),

- n.m.r. δ values include 3.92 (s, 3H), 3.94 (s, 3H), 7.73 (d, 1H), 7.94 (dd, 1H), 8.42 (d, 1H),
from 4-bromoisophthalic acid (3.0 g) and acetyl chloride (1.8 mL) in anhydrous
15 methanol (50 mL).

Intermediate 5

3-Bromo-5-pyridinecarboxylic acid methyl ester as a pale yellow solid (2.97 g);

- 20 n.m.r. (DMSO- d_6) δ values include 3.89 (s, 3H), 8.44 (s, 1H), 8.97 (s, 1H), 9.04 (s, 1H),
from 3-bromo-5-pyridinecarboxylic acid (3.00 g).

Intermediate 6

2-Hydroxy-3-pyridinecarboxylic acid methyl ester as a white solid (1.58 g),

- 25 n.m.r. (DMSO- d_6) δ values include 3.71 (s, 3H), 6.25 (t, 1H), 7.64 (dd, 1H), 8.04 (dd, 1H), 12.08 (bs, 1H),
from 2-hydroxy-3-pyridinecarboxylic acid (2.50 g).

Intermediate 7

- 30 2-(Trifluoromethanesulfonyl)oxy-3-pyridinecarboxylic acid methyl ester

- To a stirred, cooled (-78°C) solution of 2-hydroxy-3-pyridinecarboxylic acid methyl ester (1.12 g) in dichloromethane was added diisopropylamine (1.04 g) dropwise. The mixture was stirred for 20 min and then trifluoromethanesulfonic anhydride (2.18 g) was added dropwise. After 30 min, the mixture was
35 quenched with water, warmed to room temperature and extracted with

dichloromethane. The organic layer was dried over magnesium sulfate. The solvent was removed under reduced pressure and the residue was chromatographed on silica gel eluting with 1:4 ethyl acetate in hexane to provide the title compound (1.66 g) as a white solid.

- 5 Electrospray MS (positive ion): (M+H) 307.
n.m.r. (DMSO- d_6) δ values include 3.90 (s, 3H), 7.78 (dd, 1H), 8.58 (dd, 1H), 8.69 (dd, 1H).

Intermediate 8

10 2-Bromo-4-pyridinecarboxylic acid ethyl ester

To a suspension of 2-bromo-4-pyridine carboxylic acid (prepared according to the method of Ashimori, *Chem. Pharm. Bull.* 38 (9) 2446-2458 (1990)) in 2:1 toluene: absolute ethanol (45 mL) was added sulfuric acid (0.75 mL). The mixture was heated at reflux for 16 h. The mixture was poured into saturated aqueous sodium bicarbonate and extracted with chloroform (3 times). The combined chloroform extracts were dried over magnesium sulfate, filtered and concentrated afforded the crude product as a yellow oil. Purification by silica gel chromatography eluting with 9:1 hexane:ethyl acetate to afford the title compound (900 mg) as a clear, colorless oil.

- 15
20 n.m.r. δ values include 1.39 (t, 3H), 4.40 (q, 2H), 7.79 (d, 1H), 8.02 (s, 1H), 8.50 (d, 1H).

Intermediate 9

2-Bromo-6-pyridine-carboxylic acid

- 25 To deionized water (75 mL) was added 2-bromo-6-methylpyridine (5.0 g) and potassium permanganate (4.74 g). After refluxing for 1 h another portion of potassium permanganate (4.74 g) in deionized water (75 mL) was added. The mixture was heated at reflux for an additional 5 h and filtered through celite. The filtrate was acidified with 6N hydrochloric acid and the product precipitated as a white solid. The solid was collected by suction filtration and the filtrate was extracted with ethyl acetate, dried over sodium sulfate, filtered and concentrated to yield more title product (total 2.65 g).
m.p. 189-191°C

35 Intermediate 10

2-Bromo-6-pyridine-carboxylic acid ethyl ester

Sulfuric acid (1.46 mL) was added to a mixture of 2-bromo-6-pyridine-carboxylic acid, ethanol (15 mL) and toluene (30 mL). The reaction heated to reflux for 16 h. The mixture was partitioned between chloroform and a saturated aqueous solution of sodium bicarbonate. The aqueous layer was extracted with chloroform (2x) and the combined organic layers were dried over sodium sulfate, filtered and concentrated to yield a cloudy orange oil. The oil was purified by silica gel chromatography with 9:1 hexane:ethyl acetate. The title product was obtained as an oily white solid (1.31 g).

n.m.r.(CD₃OD) δ values include 1.39 (t, 3 H), 4.41 (q, 2H), 7.79 (d, 2H), 7.85 (t, 1H), 8.08 (d, 1H).

Intermediate 113'-Nitro-[1,1'-biphenyl]-4-carboxylic acid methyl ester

To a stirred mixture of methyl 4-bromobenzoate (1.00 g) and 3-nitrophenylboronic acid (800 mg) in dioxane (20 mL) was added tetrakis(triphenylphosphine)palladium(0) (165 mg) and solid sodium carbonate (710 mg). The mixture was heated at 85°C overnight, cooled to room temperature and partitioned between dichloromethane (100 mL) and 2M aqueous sodium carbonate (50 mL) containing concentrated ammonium hydroxide (5 mL). The aqueous layer was further extracted twice with dichloromethane. The combined organic layers were washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. The residue was absorbed onto silica and chromatographed on silica gel eluting with 6:94 ethyl acetate in hexane to provide the title compound (198 mg) as a white solid n.m.r. (DMSO-d₆) δ values include 3.88 (s, 3H), 7.79 (t, 1H), 7.95 (dd, 2H), 8.07 (dd, 2H), 8.24 (m, 21H), 8.504 (t, 1H).

Similarly prepared were:

Intermediate 12

3'-Nitro-[1,1'-biphenyl]-2-carboxylic acid methyl ester as a white solid (1.81 g); n.m.r. (DMSO-d₆) δ values include 3.61 (s, 3H), 7.51 (d, 1H), 7.58 (t, 1H), 7.69 (m, 3H), 7.88 (d, 1H), 8.24 (d, 1H);

from methyl 2-bromobenzoate (1.53 g), tetrakis(triphenylphosphine)palladium(0) (270 mg) and 3-nitrophenylboronic acid (1.44 g).

Intermediate 13

5 3'-Nitro-[1,1'-biphenyl]-3-carboxylic acid methyl ester as a brown solid (2.28 g);
n.m.r. δ values include 3.96 (s, 3H), 7.57 (t, 1H), 7.64 (t, 1H), 7.81 (d, 1H), 7.94
(d, 1H), 8.09 (d, 1H), 8.23 (dd, 1H), 8.30 (s, 1H), 8.48 (t, 1H), m.p., 88-90 °C;
from methyl 3-bromobenzoate (2.0 g), tetrakis(triphenylphosphine)palladium(0)
(348mg) and 3-nitrophenylboronic acid (1.9 g).

Intermediate 14

3-(3-Nitrophenyl)-5-pyridinecarboxylic acid methyl ester

Intermediate 14 was prepared as a tan solid (296 mg);

Assay Found: C 60.61; H 3.93; N 10.78%

15 $C_{13}H_{10}N_2O_4$ requires C 60.47; H 3.90; N 10.85%;

from 3-bromo-5-pyridinecarboxylic acid methyl ester (1.00 g) and 3-
nitrophenylboronic acid (785 mg) tetrakis(triphenylphosphine)palladium(0) (164
mg).

Intermediate 15

20 2-(3-Nitrophenyl)-3-pyridinecarboxylic acid methyl ester as a tan solid (301 mg);
n.m.r. (DMSO- d_6) δ values include 3.69 (s, 3H), 7.75 (dd, 1H), 7.94 (dd, 1H),
8.29 (m, 3H), 8.86 (dd, 1H);

from 2-(trifluoromethanesulfonyl)oxy-3-pyridinecarboxylic acid methyl ester
25 (506mg) 3-nitrophenylboronic acid (325 mg) and tetrakis-
(triphenylphosphine)palladium(0) (70 mg).

Intermediate 16

30 3'-Nitro-[1,1'-biphenyl]-3,4-dicarboxylic acid dimethyl ester as a brown solid (1.6
g);

n.m.r. δ values include 3.93 (s, 3H), 3.94 (s, 3H), 7.65 (t, 1H), 7.78 (dd, 1H),
7.86 (d, 1H), 7.92-7.95 (m, 2H), 8.26 (dd, 1H), 8.46 (t, 1H);

from dimethyl 4-bromophthalate (1.80 g),

tetrakis(triphenylphosphino)palladium(0) (246mg) and 3-nitrophenylboronic acid
35 (1.3 g).

Intermediate 17

3'-Nitro-[1,1'-biphenyl]-3-chloro-4-carboxylic acid methyl ester as a brown solid (2.03 g);

n.m.r. δ values include 3.96 (s, 3H), 7.56 (dd, 1H), 7.65 (t, 1H), 7.71 (d, 1H), 7.91 (d, 1H), 7.97 (d, 1H), 8.27 (d, 1H), 8.47 (m, 1H);
from methyl 4-bromo-2-chlorobenzoate (2.0 g),
tetrakis(triphenylphosphino)palladium(0) (299 mg) and 3-nitrophenylboronic acid (1.6 g).

Intermediate 18

3'-Nitro-[1,1'-biphenyl]-2-methyl-5-carboxylic acid methyl ester as a tan solid (605mg);

Assay found C, 66.36, H, 4.87, 5.15

$C_{15}H_{13}N_1O_4$ requires C, 66.41, H, 4.83, N, 5.16;

from methyl 3-bromo-4-methylbenzoate (2.3 g) in toluene (28 mL),
tetrakis(triphenylphosphino)palladium(0) (381mg) and 3-nitrophenylboronic acid (2.03 g) in methanol (7 mL).

Intermediate 19

3'-Nitro-[1,1'-biphenyl]-2,4-dicarboxylic acid dimethyl ester as a tan solid (880 mg);

Electrospray MS (positive ion): (M+Na) 338;

from dimethyl 4-bromoisophthalate (1.26 g), 3-nitrophenylboronic acid (795 mg) and tetrakis(triphenylphosphine)palladium(0) (167 mg).

Intermediate 20

5-(3-Nitrophenyl)-2,3-dihydro-7-benzofurancarboxylic acid methyl ester as a pale yellow solid (650mg);

m.p. 53-57 °C;

from 5-bromo-2,3-dihydro-7-benzofurancarboxylic acid methyl ester (1.0 g),
tetrakis(triphenylphosphino)palladium(0) (103mg), 2M sodium carbonate (7.0 mL) and 3-nitrophenylboronic acid (741mg) in methanol (5 mL).

Intermediate 21

3-(3-Nitrophenyl)-5-pyridinecarboxylic acid ethyl ester as a pale yellow solid (400mg);

n.m.r. δ values include 1.5 (t, 3H), 4.5 (q, 2H), 7.75 (t, 1H), 8.0 (d, 1H), 8.3 (d, 1H), 8.6-8.5 (m, 2H), 9.0 (s, 1H), 9.3 (s, 1H);

5 from 3-bromo-5-pyridine carboxylic acid ethyl ester (985mg) in toluene (15 mL), tetrakis(triphenylphosphino)palladium(0) (161 mg) and 3-nitrophenylboronic acid (860mg).

Intermediate 22

10 2-(3-Nitrophenyl)-4-pyridinecarboxylic acid ethyl ester as a white solid (355 mg);

Electrospray MS (positive ion): (M+H) 272.8;

from 2-bromo-4-pyridinecarboxylic acid ethyl ester (900 mg),

tetrakis(triphenylphosphine)palladium (136 mg), and 3-nitrophenylboronic acid (783 mg).

15

Intermediate 23

Methyl 3-(3-methoxyphenyl)-benzoate as a clear colorless liquid (3.34 g);

^1H NMR δ values include 3.86 (s, 3H), 3.93 (s, 3H), 6.91 (dd, 1H), 7.13 (s, 1H), 7.76 (d, 1H), 8.00 (d, 1H), 8.26 (s, 1H)

20 from methyl 3-bromobenzoate (5.82 g), tetrakis(triphenylphosphine)palladium (1.0 g) and 3-methoxyphenylboronic acid (5.0 g).

Intermediate 24

3'-Nitro-[1,1'-biphenyl]-3-carbonitrile as a yellow solid (1.96g),

25 m.p. 169-173°C;

from 3-bromobenzonitrile (2.0g) in toluene (20mL), 3-nitrophenylboronic acid (2.2g), and tetrakis(triphenylphosphine)palladium(0) (381mg) in methanol (5 mL).

30 Intermediate 25

6-(3-nitrophenyl)-2-pyridine-carboxylic acid methyl ester and 6-(3-nitrophenyl)-2-pyridine-carboxylic acid ethyl ester as a yellow solid (289 mg) judged by n.m.r. to be 2.7:1 mixture of ethyl: methyl esters;

n.m.r δ values include 1.47 (t, 2.9H), 4.04 (s, 0.8 H), 4.50 (q, 1.46 H), 7.67 (t, 1H), 7.97-7.99 (m, 2H), 8.10-8.16 (m, 1H), 8.29 (d, 1H), 8.43-8.48 (m, 1H), 8.86-8.87 (m, 1H);

5 from 2-bromo-6-pyridine-carboxylic acid ethyl ester (1.2 g) in toluene (20 mL), tetrakis(triphenylphosphine) palladium(0) (181 mg), 2M aqueous sodium carbonate (3.3 mL), and 3-nitrophenylboronic acid (1.0 g) in methanol (5 mL).

Intermediate 26

3'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid methyl ester

10 To a -78 °C solution of methyl 3-(3-methoxyphenyl)-benzoate (1.48 g) in anhydrous methylene chloride (16 mL) was added dropwise a solution of boron tribromide in methylene chloride (1.0 M, 16.3 mL). The mixture was stirred at -78 °C for 30 min, allowed to warm to 0 °C, and stirred for 2 h. The mixture was
15 quenched by addition of saturated aqueous sodium bicarbonate (50 mL), and diluted with methylene chloride (50 mL). The mixture was placed in a separatory funnel, and the organic layer was separated, dried over sodium sulfate, filtered and concentrated to give the crude product. Purification by silica gel chromatography (eluting with 5:1 hexanes/ethyl acetate) afforded the title compound (769 mg) as a pale yellow oil.
20 NMR δ values include 3.94 (s, 3H), 6.84 (d, 1H), 7.09 (s, 1H), 7.18 (d, 1H), 7.31 (t, 1H), 7.49 (t, 1H), 7.75 (d, 1H), 8.01 (d, 1H), 8.25 (s, 1H).

Intermediate 27

3'-Nitro-biphenyl-3-(1H-5-tetrazole)

25 To a stirred mixture of 3'-nitro-[1,1'-biphenyl]-3-carbonitrile (800 mg) and trimethylsilyl azide (823 mg) in toluene (10mL) was added dimethyltin oxide (59.3 mg). The reaction was heated to 100°C overnight. The mixture was concentrated, diluted with methanol (5 mL) and concentrated again. The mixture was partitioned between a saturated solution of sodium bicarbonate and
30 ethyl acetate. The organic layer was extracted again with a sodium bicarbonate solution and the combined aqueous layers were acidified with 1N hydrochloric acid and extracted with ethyl acetate. The combined organic extracts were then dried over magnesium sulfate, filtered and concentrated to yield a white solid (377mg).
35 m.p. 271-273 °C.

Intermediate 283'-Amino-[1,1'-biphenyl]-3-carboxylic acid methyl ester

To a stirred solution of 3'-nitro-[1,1'-biphenyl]-3-carboxylic acid methyl ester (4.47 g) in anhydrous tetrahydrofuran (125 mL) under a blanket of nitrogen was added 10% palladium on activated charcoal (860mg). The reaction was evacuated and placed under a hydrogen atmosphere and stirred overnight. The reaction mixture was filtered through Celite and the solvent was removed under reduced pressure to yield a gray oil (4.4 g). The residue was chromatographed on silica eluting with 3:1 hexane:ethyl acetate. Concentration of the appropriate fractions provided the title compound as a white solid (3.5 g).

n.m.r. δ values include 3.83 (s, 2H), 3.93 (s, 3H), 6.70 (d, 1H), 6.93 (d, 1H), 7.00 (d, 1H), 7.25-7.21 (m, 1H), 7.47 (t, 1H), 7.73 (d, 1H), 7.98 (d, 1H), 8.23 (d, 1H)

Similarly prepared were:

Intermediate 29

3'-Amino-[1,1'-biphenyl]-4-carboxylic acid methyl ester as a pale yellow solid (170 mg);

Electrospray MS (positive ion): (M+H) 228;
from 3'-nitro-[1,1'-biphenyl]-4-carboxylic acid methyl ester (196 mg).

Intermediate 30

3'-Amino-[1,1'-biphenyl]-2-methyl-5-carboxylic acid methyl ester as a white crystalline solid (572 mg);

Electrospray MS (positive ion): (M+H) 242.5;
from 3'-nitro-[1,1'-biphenyl]-2-methyl-5-carboxylic acid methyl ester (605 mg).

Intermediate

3'-Amino-[1,1'-biphenyl]-2-carboxylic acid methyl ester as a pale yellow solid (910 mg);

n.m.r. (DMSO- d_6) δ values include 3.58 (s, 3H), 5.13 (s, 2H), 6.38 (d, 1H), 6.51 (m, 2H), 7.02 (t, 1H), 7.40 (m, 2H), 7.58 (m, 2H);

from 3'-nitro-[1,1'-biphenyl]-2-carboxylic acid methyl ester (1.05 g).

Intermediate 32

5-(3-Aminophenyl)-3-pyridinecarboxylic acid ethyl ester as a pale yellow solid (19.9 mg);

n.m.r. δ values include 1.42 (t, 3H), 4.43 (q, 2H), 6.75 (dd, 1H), 6.90 (t, 1H), 6.98 (d, 1H), 8.43 (t, 1H), 8.95 (d, 1H), 9.16 (d, 1H);

from 5-(3-nitrophenyl)-3-pyridinecarboxylic acid ethyl ester (100 mg).

Intermediate 33

3'-Amino-[1,1'-biphenyl]-2,4-dicarboxylic acid dimethyl ester (458 mg),

n.m.r. (DMSO- d_6) δ values include 3.64 (s, 3H), 3.88 (s, 3H), 5.21 (s, 2H), 6.41 (d, 1H), 6.52 (s, 1H), 6.56 (d, 1H), 7.06 (t, 1H), 7.54 (d, 1H), 8.10 (d, 1H), 8.17 (s, 1H);

from 3'-nitro-[1,1'-biphenyl]-2,4-dicarboxylic acid dimethyl ester (556 mg).

Intermediate 34

5-(3-Aminophenyl)-3-pyridinecarboxylic acid methyl ester (187 mg);

n.m.r. (DMSO- d_6) δ values include 3.91 (s, 3H), 5.28 (s, 2H), 6.64 (m, 1H), 6.89 (m, 2H), 7.15 (t, 1H), 8.34 (s, 1H), 9.02 (s, 2H);

from 5-(3-nitrophenyl)-3-pyridinecarboxylic acid methyl ester (220 mg).

Intermediate 35

3'-Amino-[1,1'-biphenyl]-3-carbonitrile as a yellow oil (229 mg);

n.m.r. δ values include 3.80 (bs, 2H), 6.72 (dd, 1H), 6.84 (s, 1H), 6.92 (d, 1H), 7.22-7.26 (m, 2H), 7.50 (t, 1H), 7.59 (d, 1H), 7.76 (d, 1H), 7.82 (s, 1H);

from 3'-nitro-[1,1'-biphenyl]-3-carbonitrile (430 mg).

Intermediate 36

5-(3-Aminophenyl)-4-pyridinecarboxylic acid ethyl ester

To a solution of 5-(3-nitrophenyl)-4-pyridinecarboxylic acid ethyl ester in ethyl acetate (20 mL) was added tin(II) chloride (1.47 g). The mixture was heated at 80 °C for 45 min, then allowed to cool to ambient temperature. The mixture was poured into ice and saturated aqueous sodium bicarbonate was added until the mixture attained a pH of approximately 7. Celite and ethyl acetate were added, and the mixture was stirred for 10 min. The mixture was filtered and placed in a separatory funnel. The organic layer was separated, dried over sodium sulfate,

filtered and concentrated to yield the crude product. Purification by silica gel chromatography (4:1 hexane: ethyl acetate) afforded the title compound as an orange oil (216 mg).

n.m.r. δ values include 1.42 (t, 3H), 4.43 (q, 2H), 6.86 (d, 1H), 7.29 (t, 1H), 7.44 (d, 1H), 7.51 (s, 1H), 7.78 (d, 1H), 8.26 (s, 1H), 8.80 (d, 1H).

Similarly prepared were:

Intermediate 37

3'-Amino-[1,1'-biphenyl]-3-chloro-4-carboxylic acid methyl ester (788mg); n.m.r. δ values include 3.93 (s, 3H), 6.72 (d, 1H), 6.88 (s, 1H), 6.96 (d, 1H), 7.25 (m, 1H), 7.49 (dd, 1H), 7.64 (d, 1H), 7.89 (d, 1H); from 3'-nitro-[1,1'-biphenyl]-3-chloro-4-carboxylic acid methyl ester (1.0 g) and tin (II) chloride (3.9 g).

Intermediate 38

2-(3-Aminophenyl)-3-pyridinecarboxylic acid methyl ester (275mg); n.m.r. (DMSO- d_6) δ values include 3.65 (s, 3H), 5.19 (s, 2H), 6.58 (dt, 2H), 6.76 (s, 1H), 7.05 (t, 1H), 7.44 (dd, 1H), 8.02 (d, 1H), 8.73 (d, 1H); from 2-(3-nitrophenyl)-3-pyridinecarboxylic acid methyl ester (293 mg) and 10% Pd/C (30 mg).

Intermediate 39

3'-Amino-[1,1'-biphenyl]-3,4-dicarboxylic acid dimethyl ester (680 mg); n.m.r. (DMSO- d_6) δ values include 3.77 (s, 2H), 3.91 (s, 3H), 3.92 (s, 3H), 6.70 (m, 1H), 6.89 (s, 1H), 6.97 (d, 1H), 7.21 (d, 1H), 7.69 (m, 1H), 7.79 (d, 1H), 7.85 (m, 1H); from 3'-nitro-[1,1'-biphenyl]-3,4-dicarboxylic acid dimethyl ester (0.8 g) and 10% Pd/C (560 mg) in tetrahydrofuran (30 mL).

Intermediate 40

5-(3-Aminophenyl)-2,3-dihydro-7-benzofurancarboxylic acid methyl ester
5-(3-Nitrophenyl)-2,3-dihydro-7-benzofurancarboxylic acid methyl ester (650 mg) and tin(II) chloride (2.3 g) in ethyl acetate (28 mL) were heated at 70 °C for 16 h. The mixture was allowed to cool and poured onto ice. The pH was

adjusted to 7-8 by addition of saturated aqueous sodium bicarbonate, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, treated with charcoal and dried over sodium sulfate. Filtration and removal of solvent afforded the title compound as an oil (470 mg).

5 Electrospray MS (positive ion): (M+H) 270.4.

Similarly prepared were:

Intermediate 41

10 Amino-[1,1'-biphenyl]-3-(1H-5-tetrazole) as a light brown oil (57 mg);
n.m.r. (CD₃OD) δ values include 6.75 (d, 1H), 7.02-7.07 (m, 2H), 7.20 (t, 1H),
7.54 (t, 1H), 7.69 (d, 1H), 7.96 (d, 1H), 8.25 (s, 1H); from 3'-Nitro-[1,1'-biphenyl]-
3-(1H-5-tetrazole) (371 mg) and tin(II) chloride (1.57 g).

15 Intermediate 42

6-(3-aminophenyl)-2-pyridine-carboxylic acid methyl ester and 3-(3-aminophenyl)-2-pyridine-carboxylic acid ethyl ester as a brown oil (126 mg) believed to be a 1:2.5 mixture of the methyl and ethyl esters;
Electrospray MS (positive ion): (M+H) 229.2 and 243.2;
20 from 6-(3-nitrophenyl)-2-pyridine-carboxylic acid methyl ester and 6-(3-nitrophenyl)-2-pyridine-carboxylic acid ethyl ester (280 mg) and tin(II) chloride (1.16 g).

Intermediate 43

25 Methyl 3'-[2-[[[(tert-butoxy)carbonyl]amino]ethoxy]-[1,1'-biphenyl]-3-carboxylate

A mixture of 3'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid methyl ester (667 mg) and 2-bromo-1-[(tert-butoxycarbonyl)amino]ethane (980 mg) in N, N-dimethylformamide (15 mL) was treated with potassium carbonate (2.0 g). The mixture was stirred at room temperature for 30 min, and heated to 50 °C in an oil
30 bath for 14 h. Additional bromide (396 mg) was added and the mixture was heated an additional 36 h. The mixture was cooled to room temperature and partitioned between 1:1 hexane ethyl acetate and water. The organic layer was separated, washed with water, dried over sodium sulfate, filtered and concentrated to give the crude product. Purification by silica gel

chromatography (eluting with 5:1 hexane/ethyl acetate) afforded the title compound as a colorless oil (826 mg).

NMR δ values include 1.44 (s, 9H), 3.56 (m, 2H), 3.93 (s, 3H), 4.07-4.11 (m, 2H), 5.01 (s, 1H), 6.89-6.91 (m, 1H), 7.13 (s, 1H), 7.36 (t, 1H), 7.49 (t, 1H), 7.75 (d, 1H), 8.01 (d, 1H), 8.24 (s, 1H).

Intermediate 44

Methyl 3'-[(2-[[[(tert-butoxy)carbonyl]amino]acetyl]amino)]-[1,1'-biphenyl]-3-carboxylate

To a mixture of 3'-amino-[1,1'-biphenyl]-3-carboxylic methyl ester (1.14 g) and N-(tert-butoxycarbonyl)glycine (0.879 g) in methylene chloride (20 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.20 g). The mixture was stirred for 3 h at room temperature, then washed twice with 1 N aqueous HCl, twice with saturated aqueous sodium bicarbonate and once with brine. The mixture was dried over sodium sulfate, filtered and concentrated to give a foam. Purification by silica gel chromatography eluting with 7:3 hexane/ethyl acetate gave 1.6 g of the title compound as a colorless oil. Electrospray MS (positive ion): (M+Na) 407.0.

Intermediate 45

Methyl 3'-[(2-[[[(tert-butoxy)carbonyl]amino]ethyl]amino)]-[1,1'-biphenyl]-3-carboxylate

To methyl 3'-[(2-[[[(tert-butoxy)carbonyl]amino]acetyl]amino)]-[1,1'-biphenyl]-3-carboxylate (1.6 g) 0 °C was added a 1.0 M solution of borane in tetrahydrofuran (30mL). The mixture was warmed to room temperature and stirred for 3 h. The mixture was quenched with saturated aqueous sodium bicarbonate and concentrated to leave a cloudy liquid that was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The separated organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated to give the crude product. Purification by silica gel chromatography provided the title compound (740 mg).

Electrospray MS (positive ion): M+Na 393.0

Intermediate 46

Methyl-3'-[(-2-aminoethyl)amino]-[1,1'-biphenyl]-3-carboxylate

To methyl-3'-[(2-[[[(tert-butoxy)carbonyl]amino]ethyl)amino]-[1,1'-biphenyl]-3-carboxylate (730 mg) was added 4N HCl in dioxane (20mL) and the mixture was stirred under nitrogen for 16 h. The white mixture was diluted with ether, and the dihydrochloride salt of the title compound was collected as a white solid (566 mg) by suction filtration. A portion of this material (128 mg) was partitioned between saturated aqueous sodium bicarbonate (30 mL) and ethyl acetate (30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated to give the title compound (117 mg) as a colorless oil.

Electrospray MS (positive ion): (M+H) 272

Intermediate 47

(R)-(-)-3-(Phenyloxy)-1,2-epoxypropane (U7924-89-2)

To a solution of phenol (336 mg) in anhydrous N,N-dimethylformamide (16 mL) was added sodium hydride (60% in mineral oil, 190 mg). The mixture was stirred for 1 h and (2S)-(+)-glycidyl 3-nitrobenzene sulfonate (1.0 g) in N,N-dimethylformamide (5 mL) was added. The mixture was heated to 60 °C and stirred for 30 min. The reaction was allowed to cool to room temperature, water (100 mL) was added and the mixture was extracted with 2:1 hexane:ethyl acetate (2 times 40 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated to supply the crude product. Purification by silica gel chromatography (eluting with 10:1 hexane: ethyl acetate) afforded the title compound (474 mg) as a colorless oil. NMR δ values include 2.75 (dd, 1H), 2.90 (t, 1H), 3.35 (t, 1H), 3.95 (dd, 1H), 4.20 (dd, 1H), 6.90-6.97 (m, 3H), 7.24-7.30 (m, 2H).

Intermediate 48

Methyl-3'-[(2-amino)ethoxy]-[1,1'-biphenyl]-3-carboxylate

The methyl-3'-[2-[[[(tert-butoxy)carbonyl]amino]ethoxy]-[1,1'-biphenyl]-3-carboxylate (659 mg) was dissolved in methylene chloride (25 mL) and trifluoroacetic acid (2.5 mL) was added. The mixture was stirred at room temperature for 6 h, additional trifluoroacetic acid (1.0 mL) was added and the mixture was stirred overnight. The mixture was concentrated and partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. The organic layer was separated, dried over sodium sulfate, filtered and concentrated to give the crude product. This residue was partitioned between

1:1 hexane: ethyl acetate and 1 N aqueous HCl. The aqueous layer was separated, washed with 1:1 hexane: ethyl acetate and made basic by addition of solid sodium bicarbonate. The mixture was extracted twice with ethyl acetate, and the combined organic extracts were dried over sodium sulfate, filtered and concentrated to afford the title compound (474 mg) as a colorless oil. Electro spray MS (positive ion): (M+H) 272.0.

Intermediate 49

(R)-3'-[2-[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethoxy]-[1,1'-biphenyl]-3-carboxylic acid methyl ester

A solution of methyl-3'-[(2-amino)ethoxy]-[1,1'-biphenyl]-3-carboxylate (284.5 mg) and (R)-(-)-3-chlorostyrene oxide (124 mg) in nitromethane (4.0 mL) was heated at 70-75 °C for 20 h. The mixture was concentrated with a rotary evaporator to afford the crude product. Purification by silica gel chromatography (eluting with ethyl acetate followed by 10:1 ethyl acetate: methanol followed by 3:1 ethyl acetate: methanol) afforded the title compound (190.6 mg) as a colorless oil.

Electro spray MS (positive ion): (M+H) 425.9.

Similarly prepared was:

Intermediate 50

(R)-3'-[2-[2-(2-Hydroxy-3-phenoxypropyl)amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester as a reddish oil (37 mg);

Electro spray MS (positive ion): (M+H) 421.1;
from methyl-3'-[(2-aminoethyl)amino]-[1,1'-biphenyl]-3-carboxylate (117 mg) and (R)-(-)-3-(phenoxy)-1,2-epoxypropane (54 mg).

Intermediate 51

(R)-2-(3,5-Dichlorophenyl)-2-hydroxyethanoic acid

The title compound was prepared from the corresponding cyanohydrin, which was obtained from 3,5-dichlorobenzaldehyde by a modification of the procedure employed by Huuhtranen and Kanerva for the synthesis of optically active aliphatic cyanohydrins (*Tetrahedron Asymmetry* 1992, 3, 1223). The procedure of Ziegler et al. was used to convert the cyanohydrin to the mandelic acid

(*Synthesis* 1990, 575). Defatted almond meal (18.0 g, Sigma) was wetted with aqueous citrate buffer (45 mL, 0.018 M, pH 5.5). After 15 min, isopropyl ether (405 mL) was added to the moist solid, followed by 3,5-dichlorobenzaldehyde (16.07 g) and acetone cyanohydrin (24.90 mL). The mixture was then shaken at 400 rpm in a sealed flask at room temperature for 24 h. The mixture was filtered, and the almond meal was extracted with ethyl acetate. The extracts were combined with the filtrate, and concentrated to a yellow oil, which was dissolved in concentrated hydrochloric acid (27 mL). The solution was stirred at 75 °C for 4 h. The resulting thick white slurry was cooled, diluted with water (100 mL), and extracted with ether. The ether extracts were in turn extracted with 1 M aqueous sodium hydroxide solution. Acidification of the basic extracts to pH 1 (pH paper) by the dropwise addition of concentrated hydrochloric acid caused an oil to separate out of the aqueous phase. This mixture was then extracted with ether. These extracts were dried (magnesium sulfate), and concentrated to afford the title compound as an off-white crystalline solid (20.88 g). mp: 105-106 °C.

Intermediate 52

Methyl (R)-2-(3,5-dichlorophenyl)-2-hydroxyethanoate

A solution of (R)-2-(3,5-dichlorophenyl)-2-hydroxyethanoic acid (19.10 g) in methanol (200 mL) containing concentrated sulfuric acid (1 mL) was stirred at reflux under nitrogen for 16.5 h. The solution was then concentrated under vacuum, and the resulting oil was dissolved in ethyl acetate (200 mL). This solution was washed with saturated aqueous sodium bicarbonate solution, followed by saturated aqueous sodium chloride solution (10 mL). After drying (magnesium sulfate), the ethyl acetate was removed, and the yellow oil was recrystallized from hexane (70 mL) to afford the title compound as a colorless crystalline solid (10.68 g). The mother liquor afforded additional product (3.61 g) upon concentration. mp: 68-69 °C.

Intermediate 53

Methyl (R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(3,5-dichlorophenyl)ethanoate

A solution of methyl (R)-2-(3,5-dichlorophenyl)-2-hydroxyethanoate (10.485 g), tert-butyldimethylsilyl chloride (8.07 g), and imidazole (3.64 g) in N,N-

dimethylformamide (50 mL) was stirred under nitrogen for 18 h. Volatiles were then removed under vacuum and the residue was chromatographed on silica gel, eluting with hexane/ethyl acetate (20:1) The title compound was obtained as a colorless oil (15.05 g).

Assay: Found: C 51.67, H 6.29, Cl 20.19%; $C_{15}H_{22}O_3Cl_2Si$ requires C 51.57, H 6.35, Cl 20.30%;

Intermediate 54

(R)-2-[tert-Butyl(dimethyl)silyl]oxy-2-(3,5-dichlorophenyl)ethanal

Diisobutylaluminum hydride (56.5 mL, 1.5 M in toluene) was added dropwise over 1 h to a cooled (-78 °C) solution of methyl (R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(3,5-dichlorophenyl)ethanoate (14.81 g) in toluene (150 mL) under nitrogen. The resulting colorless solution was stirred at this temperature for 1 h, before a saturated aqueous solution of Rochelle's salt (70 mL) was added dropwise. The resulting mixture was allowed to warm to room temperature, and was then diluted with ethyl acetate. The biphasic system was filtered through celite, rinsing with water and ethyl acetate. The filtrate was separated into its two layers, and the aqueous layer was extracted with ethyl acetate. The extract and the organic layer of the filtrate were combined, washed with saturated aqueous sodium chloride solution, dried (magnesium sulfate), and concentrated to afford (2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(3,5-dichlorophenyl)ethanal as a colorless oil (13.36 g). Based on its 1H -NMR spectrum, the title compound made up ca. 50% of the oil.

NMR δ values include 0.15 (s, 3H), 0.21 (s, 3H), 1.03 (s, 9H), 5.00 (s, 1H), 7.22-7.39 (m, 3H), 9.56 (s, 1H).

Intermediate 55

Methyl (R)-2-(tert-butoxycarbonyl)[2-[tert-butyl(dimethyl)silyl]oxy-2-(3,5-dichlorophenyl)ethyl]aminoacetate

Glycine methyl ester hydrochloride (7.87 g) was added to a solution of crude (R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(3,5-dichlorophenyl)ethanal (13.36 g) in dichloromethane (200 mL) under nitrogen. Triethylamine (8.74 mL) was then added, and the reaction mixture was stirred for 30 min. Sodium triacetoxyborohydride (17.71 g) was added, and the yellow mixture was stirred

at room temperature for 22 h. The reaction mixture was then diluted with a saturated aqueous solution of Rochelle's salt (75 mL). The two layers were separated, and the cloudy aqueous phase was extracted with dichloromethane (70 mL). The extract was combined with the organic layer, washed with
5 saturated aqueous sodium chloride (75 mL), dried (magnesium sulfate), and concentrated under vacuum to afford a yellow oil (17.10 g).

Di-tert-butyl dicarbonate (10.56 mL) was added to the yellow oil, and the resulting solution was heated at 95 °C under nitrogen for 1 h. The solution was cooled to room temperature, and chromatographed on silica gel, eluting with
10 hexane. A colorless oil was obtained (14.221 g) that consisted of the desired product and ca. 30% (*R*)-2-[tert-butyl(dimethyl)silyl]oxy-2-(3,5-dichlorophenyl)-1-ethanol. In order to remove the alcohol, tert-butyldimethylsilyl chloride (2.11 g) and imidazole (953 mg) were added to a solution of the oil (14.221 g) in acetonitrile (60 mL). The reaction mixture was stirred under nitrogen for 2 h.
15 Volatiles were then removed under vacuum, and the residue was chromatographed on silica gel, eluting with hexane/ethyl acetate (1:0 to 10:1). In this manner, a sample of the title compound was obtained containing 4% (*R*)-2-[tert-butyl(dimethyl)silyl]oxy-2-(3,5-dichlorophenyl)-1-ethanol (10.25 g).
Low resolution MS (ES+) 514/516 (M+Na).

Intermediate 56

(R)-[[(tert-Butoxycarbonyl)-[2-(tert-butyl(dimethyl)silanyloxy)-2-(3,5-dichlorophenylethyl)]-amino]-acetaldehyde

Diisobutylaluminum hydride (1.5M in toluene, 3.9 mL) was added to methyl-
25 (R)-2-(tert-butoxycarbonyl)-[2-(tert-butyl(dimethyl)silyl]oxy-2-(3,5-dichlorophenyl)ethyl]amino}acetate (1.5 g) in toluene (25 mL) at -78 °C. The mixture was stirred for 75 min, quenched with methanol (4 mL) followed by 15% aqueous sodium potassium tartrate (10 mL). The mixture was filtered through a pad of Celite, and the filtrate was placed in a separatory funnel after addition of
30 ethyl acetate. The organic layer was separated, dried over sodium sulfate, filtered and concentrated to supply the title compound (1.3 g).
n.m.r. δ values include -0.13 (d, 3H), 0.02 (d, 3H), 0.88 (d, 9H), 1.42 (d, 9H), 2.9-3.2 (m, 1H), 3.4-3.65 (m, 1H), 3.75-4.15 (m, 2H), 4.8-5.0 (m, 1H), 7.05-7.35 (m, 3H), 9.50 (d, 1H).

Intermediate 57

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester

- 5 To a stirred solution of 3'-amino-[1,1'-biphenyl]-3-carboxylic acid methyl ester (3.0 g) and (R)-[[[(tert-butoxycarbonyl)-[2-(tertbutyldimethylsilanyloxy)-2-(3-chlorophenyl)ethyl]amino]acetaldehyde (8.2 g) in anhydrous dichloromethane (65 mL) was added acetic acid (8 drops). After stirring for twenty-five minutes, sodium triacetoxyborohydride (5.6 g) was added and the reaction stirred
10 overnight. The reaction was quenched with saturated aqueous sodium bicarbonate and more dichloromethane was added. The organic layer was dried over sodium sulfate and the solvent was removed under reduced pressure to yield a white foam. The residue was purified by silica gel chromatography and eluted with 9:1 hexane:ethyl acetate to provide the title compound as a
15 white foam (5.62 g).
Electrospray MS (positive ion): (M+H) 640.0.

Similarly prepared were:

20 Intermediate 58

3'-[[2R-[[2-(3-Chlorophenyl)-2R-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]propyl]amino]-[1,1'-biphenyl]-2-carboxylic acid methyl ester as a white foam (580 mg);

Electrospray MS (positive ion): (M+Na-Boc) 553;

- 25 from 3'-amino-[1,1'-biphenyl]-2-carboxylic acid methyl ester (375 mg) and [2R-(tert-butoxycarbonyl)-[2R-(tert-butyl)dimethylsilanoxy]-2-(3-chlorophenyl)ethyl]amino]-propionaldehyde (651 mg).

Intermediate 59

- 30 3'-[[2R-[[2-(3-Chlorophenyl)-2R-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]propyl]amino]-[1,1'-biphenyl]-4-carboxylic acid methyl ester as a white foam (296 mg);

Electrospray MS (positive ion): (M+H) 653;

from [2R-(tert-butoxycarbonyl)-[2R-(tert-butyldimethylsiloxy)-2-(3-chlorophenyl)ethyl]amino]-propionaldehyde (340 mg) and 3'-amino-[1,1'-biphenyl]-4-carboxylic acid methyl ester (168 mg).

5 Intermediate 60

3'-[[[2R-[[2-(3-Chlorophenyl)-2R-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]propyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid dimethyl ester as a yellow foam (339 mg);

Electrospray MS (positive ion): (M+H) 711;

10 from 3'-amino-[1,1'-biphenyl]-2,4-dicarboxylic acid dimethyl ester (456 mg) and [2R-(tert-butoxycarbonyl)-[2R-(tert-butyldimethylsiloxy)-2-(3-chlorophenyl)ethyl]amino]-propionaldehyde (609 mg).

Intermediate 61

15 5-[3-[[[2R-2-[[2-(3-Chlorophenyl)-2R-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]propyl]amino]phenyl]-3-pyridinecarboxylic acid methyl ester as a white foam (339 mg);

Electrospray MS (positive ion): (M+H) 654;

20 from 5-(3-aminophenyl)-3-pyridinecarboxylic acid methyl ester (185 mg) and [2R-(tert-butoxycarbonyl)-[2R-(tert-butyldimethylsiloxy)-2-(3-chlorophenyl)ethyl]amino]-propionaldehyde (317 mg).

Intermediate 62

25 2-[3-[[[2R-[[2-(3-Chlorophenyl)-2R-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]propyl]amino]phenyl]-3-pyridinecarboxylic acid methyl ester as a white foam (339 mg);

Electrospray MS (positive ion): (M+H) 654;

30 from 2-(3-aminophenyl)-3-pyridinecarboxylic acid methyl ester (273 mg) and [2R-(tert-butoxycarbonyl)-[2R-(tert-butyldimethylsiloxy)-2-(3-chlorophenyl)ethyl]amino]-propionaldehyde (504 mg).

Intermediate 63

35 (R)-3'-[[[2-[[2-(3-Chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid dimethyl ester as a foam (1.8 g);

n.m.r. δ values include -0.14 (s, 3H), -0.01 (s, 3H), 0.85 (s, 9H), 1.43 (s, 9H), 3.94 (s, 3H), 7.41 (d, 1H);

from [3'-aminophenyl]-2,4-dicarboxylic acid dimethyl ester (1.38 g) and (R)-(tert-butoxycarbonyl)-[2-(tert-butyldimethylsiloxy)-2-(3-chlorophenyl)ethyl]amino]-acetaldehyde (605 mg).

Intermediate 64

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-chloro-4-carboxylic acid methyl ester as a foam (884 mg);

n.m.r. δ values include -0.13 (s, 3H), 0.01 (s, 3H), 0.86 (s, 9H), 1.47 (s, 9H), 3.03-3.65 (m, 6H), 3.92 (s, 3H), 7.88 (d, 1H);

from 3'-amino-[1,1'-biphenyl]-3-chloro-4-carboxylic acid methyl ester (500 mg) and (R)-[(tert-butoxycarbonyl)-[2-(tert-butyldimethylsiloxy)-2-(3-chlorophenyl)ethyl]amino]-acetaldehyde (1.0 g).

Intermediate 65

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-2-methyl-5-carboxylic acid methyl ester as a white foam (509 mg);

Electrospray MS (positive ion): (M+H) 653.3;

from 3'-amino-[1,1'-biphenyl]-2-methyl-5-carboxylic acid methyl ester (500 mg) and {2R-(tert-butoxycarbonyl)-[2-(tert-butyldimethylsiloxy)-2-(3-chlorophenyl)ethyl]amino}acetaldehyde (1.3 g).

Intermediate 66

(R)-5-[3-[[2-[[2-(3-Chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]ethyl]amino]phenyl]-2,3-dihydro-7-benzofurancarboxylic acid methyl ester as a foam (691 mg);

TLC R_f (4:1 hexane/ethyl acetate) = 0.14;

from 5-(3-aminophenyl)-2,3-dihydro-7-benzofurancarboxylic acid methyl ester (500 mg) and (R)-[(tert-butoxycarbonyl)-[2-(tert-butyldimethylsiloxy)-2-(3-chlorophenyl)ethyl]amino]-acetaldehyde (1.3 g).

Intermediate 67

(R)-5-[[2-[[2-(3-Chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]ethyl]amino]-[phenyl]-3-pyridine-carboxylic acid ethyl ester as a yellow foam (372 mg);

Electrospray MS (positive ion): (M+H) 654.4;

- 5 from 5-(3-aminophenyl)-3-pyridinecarboxylic acid ethyl ester (0.19 g) and {2R-(tert-butoxycarbonyl)-[2R-(tert-butyldimethylsilanoxy)-2-(3-chlorophenyl)ethyl]amino}acetaldehyde (0.6 g).

Intermediate 68

- 10 (R)-3'-[[2-[[2-(3-Chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3,4-dicarboxylic acid dimethyl ester as a white foam (1.3 g);

Electrospray MS (positive ion): (M+H) 697.6;

- 15 from 3'-amino-[1,1'-biphenyl]-3,4-dicarboxylic acid dimethyl ester (580 mg) and (R)-[(tert-butoxycarbonyl)-[2-(tert-butyldimethylsilanoxy)-2-(3-chlorophenyl)ethyl]amino]-acetaldehyde (1.5 g).

Intermediate 69

- 20 (R)-3'-[[2-[[2-(3,5-Dichlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester as a white foam (1.1 g);

n.m.r. δ values include -0.12 (s, 3H), -0.01 (s, 3H), 0.86 (s, 9H), 1.45 (s, 9H), 3.92 (s, 3H), 7.47 (t, 1H), 7.98 (d, 1H), 8.21 (s, 1H);

- 25 from 3'-amino-[1,1'-biphenyl]-3-carboxylic methyl ester (443 mg) and (R)-[(tert-butoxycarbonyl)-[2-(tert-butyl-dimethyl-silanyloxy)-2-(3,5-dichlorophenyl)ethyl]amino]-acetaldehyde (1.3 g).

Intermediate 70

- 30 (R)-2-[3-[[2-[[2-(3-Chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butyloxy)carbonyl]amino]ethyl]amino]-[phenyl]-pyridine-carboxylic acid ethyl ester as a pale yellow foam (239 mg);

n.m.r. δ values include -0.12 (s, 3H), -0.01 (s, 3H), 0.86 (s, 9H), 1.45 (s, 9H), 3.92 (s, 3H), 7.47 (t, 1H), 7.98 (d, 1H), 8.21 (s, 1H); from 5-(3-aminophenyl)-4-pyridinecarboxylic acid ethyl ester (216 mg) and (R)-[(tert-butoxycarbonyl)-[2-

(tert-butyl-dimethyl-silanyloxy)-2-(3-chlorophenyl)ethyl]amino]-acetaldehyde (640 mg).

Intermediate 71

5 (R)-3'-[[2-[[2-(3-Chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carbonitrile as a white foam (637 mg);

Electrospray MS (positive ion): 605.7;

10 from 3'-amino-[1,1'-biphenyl]-3-carbonitrile (229 mg) and (R)-[(tert-butoxycarbonyl)-[2-(tert-butyldimethylsilyloxy)-2-(3-chlorophenyl)ethyl]amino]-acetaldehyde (753 mg).

Intermediate 72

15 (R)-6-[[2-[[2-(3-Chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]ethyl]amino]-[phenyl]-2-pyridine-carboxylic acid methyl ester and (R)-6-[[2-[[2-(3-chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]ethyl]amino]-[phenyl]-2-pyridine-carboxylic acid ethyl ester as a yellow oil (263 mg) as a 1:2.5 mixture of the methyl and ethyl esters;

20 Electrospray MS (positive ion): (M+H-BOC) 539.9 and 553.9;

from 6-(3-aminophenyl)-2-pyridine-carboxylic acid methyl ester, 6-(3-aminophenyl)-2-pyridinecarboxylic acid ethyl ester (126 mg),) and (R)-[(tert-butoxycarbonyl)-[2-(tert-butyldimethylsilyloxy)-2-(3-chlorophenyl)ethyl]amino]-acetaldehyde (490 mg).

25

Intermediate 73

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]](tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-(1H-5-tetrazole)

30 (A) To a stirred solution of (R)-[(tert-butoxycarbonyl)-[2-(tert-butyldimethylsilyloxy)-2-(3-chlorophenyl)ethyl]amino]-acetaldehyde (134 mg), and 3'-amino-[[1,1'-biphenyl]-3-[1H-5-tetrazole] (50 mg) in anhydrous methanol (35mL) was added acetic acid (45.5 mL). After stirring for 10 minutes sodium cyanoborohydride (33 mg) was added and the reaction stirred for 64 h. Worked up by partitioning between 15% Rochelle's salt and ethyl acetate. The aqueous
35 layer was extracted again with ethyl acetate. The organic layers were combined

and dried over sodium sulfate. Intermediate 74 was obtained as a white film (52 mg) after silica gel chromatography (6:1:0.1 chloroform:methanol: ammonium hydroxide);

Electrospray MS (positive ion): (M+H) 650.1

(B) To a stirred mixture of (R)-3'-[[2-[[2-(3-chlorophenyl)-2-[[tert-butyl)dimethylsilyl]oxy]ethyl][tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carbonitrile (350 mg) and trimethylsilyl azide (134 mg) in toluene (10mL) was added dimethyltin oxide (9.5 mg). The reaction was heated to 100 °C overnight. Methanol (5 mL) was added, the mixture was transferred to another flask and concentrated. The mixture was partitioned between a saturated solution of sodium bicarbonate and ethyl acetate. The organic layer was extracted again with sodium bicarbonate solution and the combined aqueous layers were acidified with 3N hydrochloric acid, extracted with ethyl acetate and the combined organic layers were dried over magnesium sulfate, filtered and concentrated to yield the crude product. Silica gel chromatography (6:1:0.1 chloroform:methanol:ammonium hydroxide) gave the title compound as a light orange foam (117 mg).

Electrospray MS (negative ion): (M-BOC-H) 547.1;

Electrospray MS (positive ion): (M-BOC+H) 549.2

Example 1

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester dihydrochloride

A solution of (R)-3'-[[2-[[2-(3-chlorophenyl)-2-[[tert-butyl)dimethylsilyl]oxy]ethyl][tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester (275mg) in 4N hydrochloric acid in dioxane (10 mL) was stirred for 3 days. Diethyl ether was added and the reaction was stirred for 20 minutes. The title compound was collected by suction filtration as a white solid (210mg);

$C_{24}H_{25}Cl_2N_2O_3$: MH⁺ calcd 425.1632, found 425.1635 Δ 0.3 mmu;
n.m.r.(CD₃OD) δ values include 3.19-3.13 (m, 1H), 3.36-3.30 (m, 3H), 3.63 (t, 2H), 3.92 (s, 3H), 4.99 (dd, 1H), 6.87 (d, 1H), 7.10 (m, 2H), 7.37-7.30 (m, 4H), 7.47 (s, 1H), 7.54 (t, 1H), 7.84 (d, 1H), 7.98 (d, 1H), 8.22 (s, 1H).

Similarly prepared were:

Example 2

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-
5 biphenyl]-2,4-dicarboxylic acid dimethyl ester dihydrochloride as a white solid
(478 mg);

$C_{26}H_{27}Cl_1N_2O_5$: MH+ calcd 483.1687, found 483.1689 Δ 0.2 mmu;

Assay Found: C 55.95; H 5.26; N 4.98%; $C_{26}H_{27}Cl_1N_2O_5 \cdot 2HCl$ requires C 56.18;
H 5.26; N 5.04%;

10 from (R)-3'-[[2-[[2-(3-chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl][[(tert-
butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid dimethyl
ester (508mg) in 4N hydrochloric acid in dioxane (10 mL).

Example 3

15 (R)-3'-[[2-[[2-(3-chlorophenyl)-2- hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-
2-methyl-5-carboxylic acid methyl ester dihydrochloride as a white solid (370
mg);

Electrospray MS (positive ion): (M+H) 439.3;

n.m.r.(CD₃OD) δ values include 2.29 (s, 3H), 3.33 (t, 2H), 3.57 (t, 2H), 3.87 (s,
20 3H), 4.97 (dd, 1H), 6.72 (m, 2H), 6.81 (d, 1H), 7.26-7.37 (m, 5H), 7.46 (s, 1H),
7.80 (s, 1H), 7.86 (d, 1H);

from (R)-3'-[[2-[[2-(3-chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl][[(tert-
butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-2-methyl-5-carboxylic acid
methyl ester (508mg) in 4N hydrochloric acid in dioxane (10 mL).

Example 4

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2- hydroxyethyl]amino]ethyl]amino]-[1,1'-
biphenyl]-3,4-dicarboxylic acid dimethyl ester dihydrochloride as a white solid
(743 mg);

30 $C_{26}H_{27}Cl_1N_2O_5$: MH+ calcd 483.1687, found 483.1682 Δ -0.5 mmu;

Assay Found: C 55.03; H 5.36; N 5.04%; $C_{26}H_{27}Cl_1N_2O_5 \cdot 0.64H_2O$ requires C
55.04; H 5.38; N 4.94%;

from (R)-3'-[[2-[[2-(3-chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl][[(tert-
butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3,4-dicarboxylic acid dimethyl
35 ester (1.1 g) in 4N hydrochloric acid in dioxane (10 mL).

Example 5

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-chloro-4-carboxylic acid methyl ester dihydrochloride as a white solid (617 mg);

$C_{24}H_{24}Cl_2N_2O_3$: MH⁺ calcd 459.1242, found 459.1235 Δ -0.7 mmu;

Assay Found: C 54.08; H 4.90; N 5.13%; $C_{24}H_{24}Cl_2N_2O_3 \cdot 2HCl$ requires C 54.15; H 4.92; N 5.26%;

from (R)-3'-[[2-[[2-(3-chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl][[(tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-chloro-4-carboxylic acid methyl ester (874mg) in 4N hydrochloric acid in dioxane (10 mL).

Example 6

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-(1H-5-tetrazole) dihydrochloride as a white solid (18.6 mg);

$C_{23}H_{23}N_6O_1Cl_1$: MH⁺ calcd 435.1700, found 435.1681 δ 1.9 mmu;

n.m.r. (CD_3OD) δ values include 3.11-3.19 (m, 1h), 3.37 (t, 2h), 3.64 (t, 2h), 4.99 (dd, 1h), 6.87 (d, 1h), 7.14-7.16 (m, 2h), 7.32-7.34 (m, 4h), 7.46 (s, 1h), 7.64 (t, 1h), 7.83 (d, 1h), 7.96 (d, 1h), 8.30 (s, 1h),

from (r)-3'-[[2-[[2-(3-chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl][[(tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-(1h-5-tetrazole) (52 mg) in 4n hydrochloric acid in dioxane (10 ml).

Example 7

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carbonitrile dihydrochloride as a white solid (105 mg);

$C_{23}H_{22}N_3O_1Cl_1$: MH⁺ calcd 392.1530, found 392.1530 Δ 0.1mmu;

Assay found: C, 59.17; H, 5.19; N 8.93% $C_{23}H_{22}N_3O_1Cl_1 \cdot 2HCl$ requires C, 59.43; H, 5.20; N 9.04%;

m.p. 191-206°C;

from (R)-3'-[[2-[[2-(3-chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl][[(tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carbonitrile (173 mg) in 4N hydrochloric acid in dioxane (10mL).

Example 8

(R)-3'-[[2-[[2-(3,5-Dichlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester dihydrochloride

(R)-3'-[[2-[[2-(3,5-Dichlorophenyl)-2-[(tert-butyl)dimethylsilyl]oxy]ethyl][(tert-butoxy)carbonyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester (1.0 g) was dissolved in 4N HCl in dioxane (10 mL) and stirred for 16 h. Addition of ether and collecting the resulting white solid gave 704 mg of a pink solid. A portion of this material (150 mg) was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate, and the organic layer was separated and concentrated to give a residue that was treated with 1 N aq. HCl in ether. Concentration, dissolving in methanol/water and lyophilization gave the title compound (82 mg) as a solid.

$C_{24}H_{24}Cl_2N_2O_3$: MH⁺ calcd 459.1242, found 459.1224 Δ -1.8 mmu
n.m.r. (DMSO- d_6) δ values include 3.06-3.30 (m, 4H), 3.85 (s, 3H), 5.01-5.04 (m, 1H), 6.71 (d, 1H), 6.91 (m, 2H), 7.22 (t, 1H), 7.42 (d, 2H), 7.56 (m, 2H), 7.89 (m, 2H), 8.10 (s, 1H).

Example 9

(R)-3'-[[2-[[2-(3,5-Dichlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid

A crude sample of (R)-3'-[[2-[[2-(3,5-dichlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester dihydrochloride (from Example 8, 557 mg), was treated with lithium hydroxide monohydrate (220 mg) in 3:1 methanol/water (28 mL) and stirred for 1 day. Additional lithium hydroxide monohydrate (22 mg) was added and the mixture was stirred overnight. The mixture was treated with 0.5 N aq. HCl until approximately pH6, and the resulting solid (400 mg) was collected by suction filtration. Silica gel chromatography (eluting with 6:2:0.1 chloroform/methanol/ammonium hydroxide) gave a solid that was triturated with hexanes. This material was treated with 1 N aqueous HCl, and the solid was washed by stirring with ethyl acetate. The solid was dried *in vacuo* to give the title compound (78.6 mg).

m.p. 197-201 °C;

$C_{23}H_{22}Cl_2N_2O_3$: MH⁺ calcd 445.1086, found 445.1072 Δ -1.4 mmu.

Example 10

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid

To a solution of the (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester (4.12 g) in methanol (60 mL) was added a solution of lithium hydroxide monohydrate (2.08 g) in water (20 mL). The mixture was stirred for 16 h, and 1 N hydrochloric acid was added until the mixture was neutral. The mixture was decanted and the residue was purified by flash silica chromatography eluting with 6:2:0.1 chloroform/methanol/ammonium hydroxide to afford a viscous oil. Trituration with ether and washing with water afforded the title compound as a white solid (2.22 g).

$C_{23}H_{23}Cl_1N_2O_3$: MH⁺ calcd 411.1475, found 411.1495 Δ 2.0 mmu;

Assay Found: C 65.90; H 5.72; N 6.70%; $C_{23}H_{23}Cl_1N_2O_3 \cdot 0.46H_2O$ requires C 65.90; H 5.75; N 6.68%

Similarly prepared were:

Example 11

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid 2-methyl ester

The product was prepared from (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid dimethyl ester dihydrochloride (406 mg) and lithium hydroxide monohydrate (262 mg) in 3:1 methanol-water (20 mL). Silica gel chromatography eluting with 6:2:0.1 chloroform:methanol:ammonium hydroxide afforded the title compound (35 mg) as a white solid.

$C_{25}H_{25}Cl_1N_2O_5$: MH⁺ calcd 469.1530, found 469.1522 Δ -0.8 mmu;

Assay found C, 63.93, H, 5.36, N, 5.91; $C_{25}H_{25}Cl_1N_2O_5$ requires C, 64.03, H, 5.37, N, 5.97

Example 12

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid

Collecting the relevant fractions from further elution of the silica gel column used to provide Example 11 gave the title compound (188 mg) as a white solid.

$C_{24}H_{23}Cl_1N_2O_5$: MH⁺ calcd 455.1374, found 455.1377 Δ +0.3 mmu;
n.m.r. (CD₃OD) δ values include 3.44-3.47 (t, 2H), 5.01 (m, 1H), 6.61 (d, 1H),
6.86 (d, 1H), 6.96 (s, 1H), 7.28-7.47 (m, 4H), 7.46 (s, 1H), 7.91 (dd, 1H), 8.11 (d,
1H).

Example 13

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-
biphenyl]-2-methyl-5-carboxylic acid as a white solid (47 mg);

$C_{24}H_{25}Cl_1N_2O_5$: MH⁺ calcd 425.1632, found 425.1638 Δ 0.6 mmu;

n.m.r. (DMSO-d₆) δ values include 2.24 (s, 3H), 4.64 (m, 1H), 5.65 (bs, 1H),
6.43-6.45 (m, 2H), 6.54 (d, 1H), 7.10 (t, 1H), 7.67 (s, 1H), 7.74 (d, 1H);
from (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-
biphenyl]-2-methyl-5-carboxylic acid methyl ester dihydrochloride (300 mg) and
lithium hydroxide monohydrate (106 mg).

Example 14

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-
biphenyl]-3-chloro-4-carboxylic acid as a yellow solid (205.3 mg);

$C_{23}H_{22}Cl_2N_2O$: MH⁺ calcd 445.1086, found 445.1071 Δ -1.5 mmu;

n.m.r. (CD₃OD) δ values include 3.10-3.24 (m, 1H), 3.56 (t, 2H), 5.00 (dd, 1H),
4.97 (d, 1H), 6.69 (d, 1H), 6.90-6.92 (m, 2H), 7.20 (t, 1H), 7.22 (t, 3H), 7.29-7.37
(m, 3H), 7.42-7.50 (m, 3H) 7.50 (d, 1H);

from (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-
biphenyl]-3-chloro-4-carboxylic acid methyl ester dihydrochloride (500 mg) and
lithium hydroxide monohydrate (158 mg).

Example 15

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-
biphenyl]-3,4-dicarboxylic acid as a yellow solid (205 mg);

$C_{24}H_{23}Cl_1N_2O_5$: MH⁺ calcd 455.1374, found 455.1390 Δ +1.6 mmu;

n.m.r. (CD₃OD) δ values include 2.97-3.00 (m, 1H), 3.43-3.45 (m, 2H), 4.97 (dd,
1H), 6.69 (d, 1H), 6.97-6.99 (m, 2H), 7.20-7.31 (m, 4H), 7.42 (s, 1H), 7.73 (d,
1H), 8.19 (d, 1H), 8.37 (s, 1H);

from (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3, 4-dicarboxylic acid dimethyl ester dihydrochloride (500 mg), and lithium hydroxide monohydrate (303 mg).

5 Example 16

(R)- 3'-[[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid as a yellow solid (23.2 mg);

C₂₄H₂₆N₂O₄: MH⁺ calcd 407.1971, found 407.1966 Δ +0.5 mmu;

10 NMR (CD₃OD): δ values include 3.14-3.20 (m, 1H), 3.54 (t, 2H), 3.95-4.04 (m, 2H), 4.23-4.27 (m, 1H), 6.67 (d, 1H), 7.38 (t, 1H), 7.62 (d, 1H), 7.65 (d, 1H), 7.88 (d, 1H), 8.19 (s, 1H);

from (R)-3'-[[2-[(2-hydroxy-3-phenoxypropyl)amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester (37 mg) and lithium hydroxide monohydrate (20 mg) in 2:1 methanol: water (1 mL).

15

Example 17

(R)-3'-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethoxy]-[1,1'-biphenyl]-3-carboxylic acid as a white solid (113.0 mg);

C₂₃H₂₂ClNO₄: MH⁺ calcd 412.1316, found 412.1308 Δ +0.8 mmu;

20 NMR (CD₃OD): δ values include 3.09-3.15 (m, 1H), 3.45 (t, 2H), 4.33 (t, 2H), 4.99 (dd, H), 5.01 (s, 1H), 6.96 (d, 1H), 7.47 (s, 1H), 7.65 (d, 1H), 7.92 (d, 1H), 8.20 (s, 1H);

from (R)-3'-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethoxy]-[1,1'-biphenyl]-3-carboxylic acid methyl ester (190.6 mg) and lithium hydroxide monohydrate (108 mg) in 3:1 methanol: water (12 mL).

25

Example 18

3'-[[2R-[[2-(3-Chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]-[1,1'-biphenyl]-4-carboxylic acid

30

A mixture of 3'-[[2R-[[2-(3-chlorophenyl)-2R-[[[(tert-butyl)dimethylsilyl]oxy]ethyl][(tert-butoxy)carbonyl]amino]propyl]amino]-[1,1'-biphenyl]-4-carboxylic acid methyl ester (289 mg) in 4N hydrochloric acid in 1,4-dioxane (4 mL) was stirred for 1.5h. The mixture was diluted with diethyl ether and stirred for 20 min to give a viscous residue. The solvent was decanted from the residue and the residue was dried under vacuum. This material was

35

dissolved in 3:1 methanol:water (10 mL), treated with lithium hydroxide monohydrate (120 mg) and stirred overnight. The mixture was concentrated under reduced pressure and chromatographed on silica eluting with methanol:dichloromethane:88% ammonium hydroxide (15:85:1.5) to give the title compound as a white solid (31 mg).

Electrospray MS (positive ion): (M+H) 425;

HPLC (C18): 98.35% purity, 12.7 minute retention time using a 10-100% acetonitrile-water with 0.1% trifluoroacetic acid.

Examples 19-25 were prepared in a similar manner as in Example 18.

Example 19

3'-[[2R-[[2-(3-Chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]-[1,1'-biphenyl]-2-carboxylic acid as a white solid (238 mg);

Electrospray MS (positive ion): (M+H) 425

HPLC (C18): 95.5% purity, 11.8 minute retention time using a 30-80% acetonitrile-water with 0.1% trifluoroacetic acid gradient mobile phase with detection by absorbance at 254 nM:

from 3'-[[2R-[[2-(3-chlorophenyl)-2R-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]][(tert-butoxy)carbonyl]amino]propyl]amino]-[1,1'-biphenyl]-2-carboxylic acid methyl ester (575 mg), 4N hydrochloric acid in 1,4-dioxane (5 mL) and lithium hydroxide monohydrate (185 mg) in 3:1 methanol-water (10 mL).

Example 20

3'-[[2R-[[2-(3-Chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid as a yellow solid (302 mg);

Electrospray MS (positive ion): (M+H) 469

HPLC (C18): 94.2% purity, 8.71 minute retention time using a 30-80% acetonitrile-water with 0.1% trifluoroacetic acid gradient mobile phase with detection by absorbance at 254 nM;

from 3'-[[2R-[[2-(3-chlorophenyl)-2R-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]][(tert-butoxy)carbonyl]amino]propyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid dimethyl ester (655 mg), 4N hydrochloric acid in 1,4-dioxane (5 mL) and lithium hydroxide monohydrate (256 mg) in 3:1 methanol-water (4 mL).

Example 21

5-[3-[[2R-[[2-(3-Chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]phenyl]-3-pyridinecarboxylic acid as a yellow solid (111 mg);

Electrospray MS (positive ion): (M+H) 426

5 HPLC (C18): 94.0% purity, 6.30 minute retention time using a 30-80% acetonitrile-water with 0.1% trifluoroacetic acid gradient mobile phase with detection by absorbance at 254 nM;

from 5-[3-[[2R-[[2-(3-chlorophenyl)-2R-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]][(tert-butoxy)carbonyl]amino]propyl]amino]phenyl]-3-pyridinecarboxylic acid methyl ester (292 mg), 4N hydrochloric acid in 1,4-dioxane (5 mL) and lithium hydroxide monohydrate (65 mg) in 3:1 tetrahydrofuran-water (3 mL).

Example 22

15 2-[3-[[2R-[[2-(3-Chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]phenyl]-3-pyridinecarboxylic acid as a yellow solid (268 mg);

Electrospray MS (positive ion): (M+H) 426;

HPLC (C18): 95.5% purity, 4.79 minute retention time using a 30-80% acetonitrile-water with 0.1% trifluoroacetic acid gradient mobile phase with detection by absorbance at 254 nM; from 2-[3-[[2R-[[2-(3-chlorophenyl)-2R-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]][(tert-butoxy)-carbonyl]amino]propyl]amino]phenyl]-3-pyridinecarboxylic acid methyl ester (420 mg), 4N hydrochloric acid in 1,4-dioxane (4 mL) and lithium hydroxide monohydrate (295 mg) in 3:1 tetrahydrofuran-water (3 mL).

Example 23

25 (R)-5-[3-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-2,3-dihydro-7-benzofurancarboxylic acid as a yellow solid (197 mg);

$C_{25}H_{25}Cl_1N_2O_4$: MH+ calcd 453.1581, found 453.1569 Δ -1.2 mmu;

30 Assay found C, 61.04, H, 5.37, N, 5.60; $C_{25}H_{25}Cl_1N_2O_4 \cdot 0.67LiCl \cdot 0.59H_2O$ requires C, 61.04, H, 5.36, N, 5.69;

from (R)-5-[3-[[2-[[2-(3-chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl]][(tert-butoxy)carbonyl]amino]ethyl]amino]phenyl]-2,3-dihydro-7-benzofurancarboxylic acid methyl ester (691 mg), 4N hydrochloric acid in 1,4-dioxane (10 mL) and lithium hydroxide monohydrate (170 mg) in 3:1 tetrahydrofuran-water (20 mL).

Example 24

(R)-5-[3-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-3-pyridinecarboxylic acid as a yellow solid (115 mg);

$C_{22}H_{22}ClN_3O_3$: MH⁺ calcd 412.1428, found 412.1425 Δ -0.3 mmu;

5 n.m.r. (CD₃OD) δ values include 3.11-3.29 (m, 1H), 3.58 (t, 2H), 4.97 (dd, 1H), 6.76 (d, 1H), 6.97 (s, 1H), 6.99 (d, 1H), 7.26-7.35 (m, 4H), 7.46 (s, 1H), 8.51 (s, 1H), 8.76 (s, 1H), 9.00 (s, 1H);

10 from (R)-5-[3-[[2-[[2-(3-chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl][[(tert-butoxy)carbonyl]amino]ethyl]amino]phenyl]-3-pyridinecarboxylic acid methyl ester (251 mg), 4N hydrochloric acid in 1,4-dioxane (10 mL) and lithium hydroxide monohydrate (96 mg) in 3:1 tetrahydrofuran-water (20 mL).

Example 25

15 (R)-2-[3-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-4-pyridinecarboxylic acid as a yellow solid (52 mg);

Electrospray MS (positive ion): (M+H) 412.1;

n.m.r. (CD₃OD) δ values include 3.11-3.17 (m, 1H), 3.58 (t, 2H), 4.96 (dd, 1H), 7.46 (s, 1H), 7.75 (d, 1H), 8.21 (s, 1H), 8.59 (d, 1H);

20 from (R)-3'-[[2-[[2-(3-chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl][[(tert-butoxy)carbonyl]amino]ethyl]amino]-[phenyl]-4-pyridine-carboxylic acid ethyl ester (239 mg), 4N hydrochloric acid in 1,4-dioxane (10 mL) and lithium hydroxide monohydrate (55 mg) in 3:1 tetrahydrofuran-water (15.5 mL).

Example 26

25 (R)-6-[3-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-2-pyridinecarboxylic acid as a yellow solid (30 mg);

$C_{22}H_{22}N_3O_3Cl$: MH⁺ calcd. 412.1428, found 412.1436 Δ +0.9mmu;

n.m.r. (CD₃OD) δ values include 3.24-3.08 (m, 2H), 3.61 (t, 2H), 5.01 (dd, 1H), 6.72 (d, 1H), 7.44 (s, 1H), 7.65 (s, 1H), 7.96-7.86 (m, 3H);

30 from a 2.5:1 mixture of (R)-6-[3-[[2-[[2-(3-chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl][[(tert-butoxy)carbonyl]amino]ethyl]amino]phenyl]-2-pyridinecarboxylic acid methyl ester and (R)-6-[3-[[2-[[2-(3-chlorophenyl)-2-[[[(tert-butyl)dimethylsilyl]oxy]ethyl][[(tert-butoxy)carbonyl]amino]ethyl]amino]phenyl]-2-pyridinecarboxylic acid ethyl ester
35 (263 mg), 4N hydrochloric acid in dioxane (10 mL) and lithium hydroxide

monohydrate (65 mg) in (3:1) methanol: water (40 mL) The intermediate ester (170 mg) was isolated by column chromatography (eluting with 12:1:0.1 chloroform:methanol:ammonium hydroxide).

5

Tablet compositions

The following compositions A and B can be prepared by wet granulation of ingredients (a) to (c) and (a) to (d) with a solution of povidone, followed by addition of the magnesium stearate and compression.

10

Composition A

		<u>mg/tablet</u>	<u>mg/tablet</u>
(a)	Active ingredient	250	250
(b)	Lactose B.P.	210	26
(c)	Sodium Starch Glycollate	20	12
15	(d) Povidone B.P.	15	9
	(e) Magnesium Stearate	<u>5</u>	<u>3</u>
		500	300

Composition B

20

		<u>mg/tablet</u>	<u>mg/tablet</u>
(a)	Active ingredient	250	250
(b)	Lactose 150	150	-
(c)	Avicel PH 101	60	26
(d)	Sodium Starch Glycollate	20	12
25	(e) Povidone B.P.	15	9
	(f) Magnesium Stearate	<u>5</u>	<u>3</u>
		500	300

Composition C

30

	<u>mg/tablet</u>
Active ingredient	100
Lactose	200
Starch	50
Povidone	5
35	Magnesium Stearate
	<u>4</u>

50

359

The following compositions D and E can be prepared by direct compression of the admixed ingredients. The lactose used in composition E is of the direct compression type.

Composition D

	<u>mg/tablet</u>
Active ingredient	250
10 Magnesium Stearate	4
Pregelatinised Starch NF15	<u>146</u>
	400

Composition E

	<u>mg/tablet</u>
15 Active ingredient	250
Magnesium Stearate	5
Lactose	145
Avicel	<u>100</u>
20	500

Composition F (Controlled release composition)

	<u>mg/tablet</u>
(a) Active ingredient	500
25 (b) Hydroxypropylmethylcellulose (Methocel K4M Premium)	112
(c) Lactose B.P.	53
(d) Povidone B.P.C.	28
(e) Magnesium Stearate	<u>7</u>
30	700

The composition can be prepared by wet granulation of ingredients (a) to (c) with a solution of povidone, followed by addition of the magnesium stearate and compression.

35

Composition G (Enteric-coated tablet)

Enteric-coated tablets of Composition C can be prepared by coating the tablets with 25mg/tablet of an enteric polymer such as cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethyl- cellulose phthalate, or anionic polymers of methacrylic acid and methacrylic acid methyl ester (Eudragit L). Except for Eudragit L, these polymers should also include 10% (by weight of the quantity of polymer used) of a plasticizer to prevent membrane cracking during application or on storage. Suitable plasticizers include diethyl phthalate, tributyl citrate and triacetin.

Composition H (Enteric-coated controlled release tablet)

Enteric-coated tablets of Composition F can be prepared by coating the tablets with 50mg/tablet of an enteric polymer such as cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethyl- cellulose phthalate, or anionic polymers of methacrylic acid and methacrylic acid methyl ester (Eudragit L). Except for Eudragit L, these polymers should also include 10% (by weight of the quantity of polymer used) of a plasticizer to prevent membrane cracking during application or on storage. Suitable plasticizers include diethyl phthalate, tributyl citrate and triacetin.

Capsule compositionsComposition A

Capsules can be prepared by admixing the ingredients of Composition D above and filling two-part hard gelatin capsules with the resulting mixture. Composition B (infra) may be prepared in a similar manner.

Composition B

		<u>mg/capsule</u>
(a)	Active ingredient	250
(b)	Lactose B.P.	143
(c)	Sodium Starch Glycollate	25
(d)	Magnesium Stearate	<u>2</u>
		420

Composition C

52

	<u>mg/capsule</u>
(a) Active ingredient	250
(b) Macrogol 4000 BP	<u>350</u>
	600

5

Capsules can be prepared by melting the Macrogol 4000 BP, dispersing the active ingredient in the melt and filling two-part hard gelatin capsules therewith.

Composition D

	<u>mg/capsule</u>
Active ingredient	250
Lecithin	100
Arachis Oil	<u>100</u>
	450

15

Capsules can be prepared by dispersing the active ingredient in the lecithin and arachis oil and filling soft, elastic gelatin capsules with the dispersion.

Composition E (Controlled release capsule)

	<u>mg/capsule</u>
(a) Active ingredient	250
(b) Microcrystalline Cellulose	125
(c) Lactose BP	125
(d) Ethyl Cellulose	<u>13</u>
	513

25

The controlled release capsule composition can be prepared by extruding mixed ingredients (a) to (c) using an extruder, then spheronising and drying the extrudate. The dried pellets are coated with a release controlling membrane (d) and filled into two-part, hard gelatin capsules.

30

Composition F (Enteric capsule)

	<u>mg/capsule</u>
(a) Active ingredient	250
(b) Microcrystalline Cellulose	125

35

(c)	Lactose BP	125
(d)	Cellulose Acetate Phthalate	50
(e)	Diethyl Phthalate	<u>5</u>
		555

- 5 The enteric capsule composition can be prepared by extruding mixed ingredients (a) to (c) using an extruder, then spheronising and drying the extrudate. The dried pellets are coated with an enteric membrane (d) containing a plasticizer (e) and filled into two-part, hard gelatin capsules.

10 Composition G (Enteric-coated controlled release capsule)

Enteric capsules of Composition E can be prepared by coating the controlled-release pellets with 50mg/capsule of an enteric polymer such as cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethylcellulose phthalate, or anionic polymers of methacrylic acid and methacrylic acid methyl ester (Eudragit L). Except for Eudragit L, these polymers should also include 10% (by weight of the quantity of polymer used) of a plasticizer to prevent membrane cracking during application or on storage. Suitable plasticizers include diethyl phthalate, tributyl citrate and triacetin.

20 Intravenous injection composition

Active ingredient	0.200g
Sterile, pyrogen-free phosphate buffer (pH 9.0) to	10 ml

- 25 The active ingredient is dissolved in most of the phosphate buffer at 35-40°C, then made up to volume and filtered through a sterile micropore filter into sterile 10 ml glass vials (Type 1) which are sealed with sterile closures and overseals.

Intramuscular injection composition

30

Active ingredient	0.20 g
Benzyl Alcohol	0.10 g
Glycofurol 75	1.45 g
Water for Injection q.s. to	3.00 ml

35

The active ingredient is dissolved in the glycofurol. The benzyl alcohol is then added and dissolved, and water added to 3 ml. The mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml glass vials (Type 1).

5

Syrup composition

	Active ingredient	0.25g
	Sorbitol Solution	1.50g
	Glycerol	1.00g
10	Sodium Benzoate	0.005g
	Flavour	0.0125ml
	Purified Water q.s. to	5.0ml

The sodium benzoate is dissolved in a portion of the purified water and the sorbitol solution added. The active ingredient is added and dissolved. The resulting solution is mixed with the glycerol and then made up to the required volume with the purified water.

20

Suppository composition

	<u>mg/suppository</u>
Active ingredient	250
Hard Fat, BP (Witepsol H15 - Dynamit NoBel)	<u>1770</u>
	2020

25

One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum. The active ingredient is sifted through a 200µm sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45°C, the remaining Witepsol H15 is added to the suspension which is stirred to ensure a homogenous mix. The entire suspension is then passed through a 250µm stainless steel screen and, with continuous stirring, allowed to cool to 40°C. At a temperature of 38-40°C, 2.02g aliquots of the mixture are filled into suitable plastic moulds and the suppositories allowed to cool to room temperature.

35

55

Pessary composition

	<u>mg/pessary</u>
Active ingredient (63lm)	250
Anhydrous Dextrose	380
5 Potato Starch	363
Magnesium Stearate	<u>7</u>
	1000

10 The above ingredients are mixed directly and pessaries prepared by compression of the resulting mixture.

Transdermal composition


Active ingredient	200mg
15 Alcohol USP	0.1ml
Hydroxyethyl cellulose	

20 The active ingredient and alcohol USP are gelled with hydroxyethyl cellulose and packed in a transdermal device with a surface area of 10 cm².

56

Claims

1. A compound of Formula (I) or a pharmaceutically acceptable derivative thereof:



(I)

wherein R¹ is a phenyl, naphthyl, pyridyl, thiazolyl, phenoxymethyl, or pyrimidyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C₁₋₆alkoxy, C₁₋₆alkyl, nitro, cyano, hydroxymethyl, trifluoromethyl, -NR⁶R⁶, and -NHSO₂R⁶, where each R⁶ is independently hydrogen or

C₁₋₄alkyl;

R² is hydrogen or C₁₋₆alkyl;

X is oxygen, sulfur, -NH, or -NC₁₋₄alkyl;

R³ is cyano, tetrazol-5-yl, or -CO₂R⁷ where R⁷ is hydrogen or C₁₋₆alkyl;

R⁴ and R⁵ are independently hydrogen, C₁₋₆alkyl, -CO₂H, -CO₂C₁₋₆alkyl, cyano, tetrazol-5-yl, halogen, trifluoromethyl, or C₁₋₆alkoxy, or, when R⁴ and R⁵ are bonded to adjacent carbon atoms, R⁴ and R⁵ may, together with the carbon atoms to which they are bonded, form a fused 5 or 6 membered ring optionally containing one or two nitrogen, oxygen, or sulfur atoms; and Y is N or CH.

2. A compound according to Claim 1 wherein R¹ is phenoxymethyl or phenyl optionally substituted by one, two, or three substituents selected from halogen, hydroxy, C₁₋₆alkoxy, C₁₋₆alkyl, nitro, cyano, hydroxymethyl, and trifluoromethyl.

3. A compound according to Claim 1 or 2 wherein R¹ is phenoxymethyl or phenyl substituted by a chlorine, fluorine, bromine, methyl, or trifluoromethyl.

4. A compound according to any one of Claims 1-3 wherein R² is hydrogen or methyl.
5. A compound according to any one of Claims 1-4 wherein R² is hydrogen.
6. A compound according to any one of Claims 1-5 wherein X is NH.
7. A compound according to any one of Claim 1-6 wherein R³ is CO₂H.
8. A compound according to any one of Claim 1-7 wherein at least one of R⁴ and R⁵ is hydrogen.
9. A compound according to any one of Claim 1-8 wherein R⁴ and R⁵ are both hydrogen.
10. A compound according to any one of Claims 1-9 wherein Y is CH.
11. A compound according to Claim 1 wherein R¹ is phenoxyethyl or phenyl substituted by a chlorine, fluorine, bromine, methyl, or trifluoromethyl; R² is hydrogen or methyl; X is NH, or NCH₃; R³ is CO₂H; and Y is CH.
12. A compound selected from the group consisting of:
 - (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester;
 - (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid dimethyl ester;
 - (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2-methyl-5-carboxylic acid methyl ester;
 - (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3,4-dicarboxylic acid dimethyl ester;
 - (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-chloro-4-carboxylic acid methyl ester;
 - (R)-3'-[[2-[[2-(3,5-dichlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid methyl ester;

(R)-3'-[[2-[[2-(3,5-dichlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid;

5 (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid 2-methyl ester;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid;

10 (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2-methyl-5-carboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-chloro-4-carboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3,4-dicarboxylic acid;

15 (R)-3'-[[2-[[2-(2-hydroxy-3-phenoxypropyl)amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethoxy]-[1,1'-biphenyl]-3-carboxylic acid;

20 3'-[[2R-[[2-(3-chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]-[1,1'-biphenyl]-4-carboxylic acid;

3'-[[2R-[[2-(3-chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]-[1,1'-biphenyl]-2-carboxylic acid;

3'-[[2R-[[2-(3-chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid;

25 5-[3-[[2R-[[2-(3-chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]phenyl]-3-pyridinecarboxylic acid;

2-[3-[[2R-[[2-(3-chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]phenyl]-3-pyridinecarboxylic acid;

30 (R)-5-[3-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-2,3-dihydro-7-benzofurancarboxylic acid;

(R)-5-[3-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-3-pyridinecarboxylic acid;

(R)-2-[3-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-4-pyridinecarboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-(1H-5-tetrazole);

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carbonitrile;

5 (R)-2-[3-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-2-pyridinecarboxylic acid;

or a pharmaceutically acceptable derivative thereof.

13. A compound selected from the group consisting of:

10 (R)-5-[3-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]phenyl]-3-pyridinecarboxylic acid;

3'-[[2R-[[2-(3-chlorophenyl)-2R-hydroxyethyl]amino]propyl]amino]-[1,1'-biphenyl]-2,4-dicarboxylic acid;

15 (R)-3'-[[2-[(2-hydroxy-3-phenoxypropyl)amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-2-methyl-5-carboxylic acid;

(R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid;

20 or a pharmaceutically acceptable derivative thereof.

14. A compound according to any one of Claims 1 to 13 for use in therapy.

15. Use of a compound according to any one of claims 1-13 in the
25 manufacture of a medicament for the treatment of of a mammal, including man, of conditions susceptible of amelioration by an atypical beta-adrenoceptor agonist.


16. A method for the treatment of a mammal, including man, of conditions
30 susceptible of amelioration by an atypical beta-adrenoceptor agonist comprising administration of an effective amount of a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof.

60

17. A pharmaceutical composition comprising a compound according to any one of claims 1-13, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers.

5 18. A process for the preparation of a compound of formula (I) comprising:



(A) deprotection of a compound of Formula (II),



10 or;

(B) interconversion of another compound of Formula (I); or

15 (C) reaction of compound of Formula (III) with a compound of Formula (IV), followed by step (A) without purification of intermediate products;




or


20

(D) reaction of a compound of Formula (VIII) with a compound of Formula (IX).

61



(VIII)



(IX)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/ 03958

Box I. Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 16
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II. Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.1

Although claim 16 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 16

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

International Application No

PC./EP 99/03958

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D213/80 C07D213/79 C07D257/04 C07D307/79 C07C215/30
 C07C217/16 C07C255/59 A61K31/19 A61K31/24 A61K31/34
 A61K31/44 A61K31/41

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 543 662 A (SANKYO CO. LTD.) 26 May 1993 (1993-05-26) cited in the application claims 1-3,48,51 ---	1-15,17
Y	WO 95 33724 A (GLAXO GROUP LTD.) 14 December 1995 (1995-12-14) cited in the application abstract; claims 1-8,11,13-15 claim 16 ---	1-15,17
A	---	18
Y	US 4 772 631 A (B. R. HOLLOWAY ET AL.) 20 September 1988 (1988-09-20) claims 1-9 ---	1-15,17
Y	US 4 478 849 A (A. T. AINSWORTH ET AL.) 23 October 1984 (1984-10-23) claims 1,27 ---	1-15,17
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

23 September 1999

Date of mailing of the international search report

01/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040. Tx. 31 651 epo nl,
 Fax: (+31-70) 340-316

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International Application No

PC., EP 99/03958

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 400 519 A (DR. K. THOMAE GMBH) 5 December 1990 (1990-12-05) claims 1,6-9; examples 1,2 ---	1-15,17
A	EP 0 455 006 A (AMERICAN CYANAMID CO.) 6 November 1991 (1991-11-06) cited in the application claims 1,11 -----	1,14,15, 17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/03958

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 543662	A	26-05-1993	AT 143002 T	15-10-1996
			AU 655689 B	05-01-1995
			AU 2849392 A	27-05-1993
			AU 670007 B	27-06-1996
			AU 7751894 A	12-01-1995
			CA 2083323 A	21-05-1993
			CN 1073428 A,B	23-06-1993
			CN 1106396 A,B	09-08-1995
			CN 1151401 A	11-06-1997
			CZ 9500345 A	17-04-1996
			CZ 280328 B	13-12-1995
			DE 69213892 D	24-10-1996
			DE 69213892 T	17-04-1997
			DK 543662 T	03-03-1997
			ES 2094308 T	16-01-1997
			FI 925255 A	21-05-1993
			GR 3021245 T	31-01-1997
			HK 218496 A	27-12-1996
			HU 66816 A	30-01-1995
			IL 103825 A	05-04-1998
			IL 110804 A	13-07-1997
			JP 9188669 A	22-07-1997
			JP 2654323 B	17-09-1997
			JP 6025118 A	01-02-1994
			MX 9206740 A	31-05-1993
			NO 179246 B	28-05-1996
			NZ 245188 A	26-07-1994
			RU 2095344 C	10-11-1997
			RU 2081113 C	10-06-1997
			US 5576340 A	19-11-1996
			US 5635534 A	03-06-1997
			ZA 9208960 A	19-05-1993
<hr/>				
WO 9533724	A	14-12-1995	AU 2737295 A	04-01-1996
			ZA 9504681 A	30-01-1996
<hr/>				
US 4772631	A	20-09-1988	AT 55980 T	15-09-1990
			AU 5992890 A	30-01-1992
			AU 603987 B	06-12-1990
			AU 6002986 A	05-02-1987
			CA 1283122 A	16-04-1991
			CN 1014516 B	30-10-1991
			CS 8605735 A	14-04-1989
			DD 251551 A	18-11-1987
			DK 359986 A	31-01-1987
			EP 0210849 A	04-02-1987
			FI 862896 A,B,	31-01-1987
			GR 861994 A	26-11-1986
			IE 60157 B	15-06-1994
			JP 1923423 C	25-04-1995
			JP 6051661 B	06-07-1994
			JP 62077357 A	09-04-1987
			JP 6340597 A	13-12-1994
			JP 8019062 B	28-02-1996
			NZ 217011 A	26-02-1990
			PH 22503 A	12-09-1988
			PT 83085 A,B	01-08-1986
			SU 1632370 A	28-02-1991

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC., EP 99/03958

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4478849 A	23-10-1984	AU 523681 B	12-08-1982
		AU 4849879 A	03-01-1980
		CA 1159072 A	20-12-1983
		DK 272779 A	04-02-1980
		EP 0006735 A	09-01-1980
		IE 48580 B	06-03-1985
		JP 1030820 B	22-06-1989
		JP 1566197 C	25-06-1990
		JP 55009085 A	22-01-1980
		MY 95885 A	31-12-1985
		MY 95985 A	31-12-1985
		NZ 190854 A	19-10-1984
		US 4654371 A	31-03-1987
		US 4753962 A	28-06-1988
		ZA 7903231 A	30-07-1980
		ES 483746 A	16-04-1980
EP 400519 A	05-12-1990	DE 3917801 A	06-12-1990
		DE 3934436 A	18-04-1991
		AU 623262 B	07-05-1992
		AU 5612790 A	06-12-1990
		CA 2017957 A	01-12-1990
		DD 297969 A	30-01-1991
		JP 3236378 A	22-10-1991
		PT 94213 A	08-02-1991
		US 5135932 A	04-08-1992
EP 455006 A	06-11-1991	US 5061727 A	29-10-1991
		AT 181914 T	15-07-1999
		AU 639094 B	15-07-1993
		AU 7607891 A	07-11-1991
		CA 2041712 A	05-11-1991
		CN 1056495 A,B	27-11-1991
		CS 9101285 A	17-12-1991
		DE 69131412 D	12-08-1999
		FI 912142 A,B,	05-11-1991
		HU 210596 B	29-05-1995
		HU 9500457 A	30-10-1995
		IL 97900 A	15-04-1997
		JP 5320153 A	03-12-1993
		NO 177822 B	21-08-1995
		PL 165665 B	31-01-1995
		PT 97540 A,B	31-01-1992
		SG 47917 A	17-04-1998
		US 5373020 A	13-12-1994
		US 5106867 A	21-04-1992
		US 5151439 A	29-09-1992
		US 5245053 A	14-09-1993

